US20160264586A1 - OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL - Google Patents
OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL Download PDFInfo
- Publication number
- US20160264586A1 US20160264586A1 US15/164,122 US201615164122A US2016264586A1 US 20160264586 A1 US20160264586 A1 US 20160264586A1 US 201615164122 A US201615164122 A US 201615164122A US 2016264586 A1 US2016264586 A1 US 2016264586A1
- Authority
- US
- United States
- Prior art keywords
- substituted
- carbonyl
- cyclobuta
- octahydro
- dipyrrol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*][Y]N1CC2C(C1)C1CN(C([2*])=O)CC21 Chemical compound [1*][Y]N1CC2C(C1)C1CN(C([2*])=O)CC21 0.000 description 21
- ZGISGTOXGYOZQG-GJVYHCGRSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC4=C(C=CC=C4)N(CCCOC)C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC4=C(C=CC=C4)N(CCCOC)C3)C[C@@]21[H] ZGISGTOXGYOZQG-GJVYHCGRSA-N 0.000 description 2
- NPEKPFKGKYRUBE-KXSOJQAOSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(C5=CC=CC=C5)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(C5=CC=CC=C5)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] NPEKPFKGKYRUBE-KXSOJQAOSA-N 0.000 description 2
- OSYVNBJNSKBFJI-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(C)OC(C4=CC=C(Cl)C=C4)=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(C)OC(C4=CC=C(Cl)C=C4)=N3)C[C@]21[H] OSYVNBJNSKBFJI-JVSBHGNQSA-N 0.000 description 2
- NPSSJSQSPJAEES-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(OCC)C4=C(C=C3)N(CC)C=C4)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(OCC)C4=C(C=C3)N(CC)C=C4)C[C@]21[H] NPSSJSQSPJAEES-ZDNVTZCJSA-N 0.000 description 2
- ZIBLANMMQWNIHX-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=CC=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=CC=C3)C[C@]21[H] ZIBLANMMQWNIHX-SEXKYXSUSA-N 0.000 description 2
- YMVZWZHLDVRELO-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C4C=CC=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C4C=CC=CC4=N3)C[C@]21[H] YMVZWZHLDVRELO-SEXKYXSUSA-N 0.000 description 2
- MIYNNFIADJPOFU-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC(OC)=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC(OC)=CC4=N3)C[C@]21[H] MIYNNFIADJPOFU-UJOPUZHASA-N 0.000 description 2
- ZWVQJXMQLPTWPF-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC4CC4)=C(Cl)C=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC4CC4)=C(Cl)C=N3)C[C@]21[H] ZWVQJXMQLPTWPF-FZDBZEDMSA-N 0.000 description 2
- TUBQGKBMDDEPOB-SYMSYNOKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CN(CC(F)(F)F)C(=O)C(Cl)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CN(CC(F)(F)F)C(=O)C(Cl)=C3)C[C@]21[H] TUBQGKBMDDEPOB-SYMSYNOKSA-N 0.000 description 2
- MRJVCAUGAWUBLV-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]21[H] MRJVCAUGAWUBLV-ZCQNZVIGSA-N 0.000 description 2
- GVYBHYZYCAAHJJ-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(C(F)(F)F)=CC=C4C(OC(C)C)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(C(F)(F)F)=CC=C4C(OC(C)C)=C3)C[C@]21[H] GVYBHYZYCAAHJJ-UJOPUZHASA-N 0.000 description 2
- RFMNMNYODLKTKY-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(Cl)=CC=C4C(OCC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(Cl)=CC=C4C(OCC)=C3)C[C@]21[H] RFMNMNYODLKTKY-JVSBHGNQSA-N 0.000 description 2
- JBMNWCJHUBUVFL-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3F)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3F)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC)=C3)C[C@]21[H] JBMNWCJHUBUVFL-SEXKYXSUSA-N 0.000 description 2
- VZLZQXMHXBRJGS-MHIYOQAPSA-N *.*.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C4C=C(Br)C=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C4C=C(Br)C=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] VZLZQXMHXBRJGS-MHIYOQAPSA-N 0.000 description 1
- RPWGCHRUHPXYKJ-MNYMAIMXSA-N *.*.*.S.[H][C@@]12CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.*.S.[H][C@@]12CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] RPWGCHRUHPXYKJ-MNYMAIMXSA-N 0.000 description 1
- XGEQNSWSENQLTC-KWUFPRQHSA-N *.*.S.S.[H][C@@]12CN(C(=O)C3=CC(OC)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.S.S.[H][C@@]12CN(C(=O)C3=CC(OC)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] XGEQNSWSENQLTC-KWUFPRQHSA-N 0.000 description 1
- FRRQPUGEALXRLX-APOBLVNVSA-N *.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] FRRQPUGEALXRLX-APOBLVNVSA-N 0.000 description 1
- ZOYJYIAUVTTXHE-KWUFPRQHSA-N *.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.S.S.[H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] ZOYJYIAUVTTXHE-KWUFPRQHSA-N 0.000 description 1
- JGNBNULLVHPDCE-CUJCHRPVSA-N *.*.S.S.[H][C@@]12CN(C(=O)C3=NC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.S.S.[H][C@@]12CN(C(=O)C3=NC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] JGNBNULLVHPDCE-CUJCHRPVSA-N 0.000 description 1
- RKLSTSLXQSUFCG-GQOAFSLDSA-N *.*.S.S.[H][C@@]12CN(C(=O)C3=NC4=CC(Cl)=CC=C4C(OCC)=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.*.S.S.[H][C@@]12CN(C(=O)C3=NC4=CC(Cl)=CC=C4C(OCC)=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] RKLSTSLXQSUFCG-GQOAFSLDSA-N 0.000 description 1
- LIJZSSLYOCZDLT-KJKCOSIVSA-N *.[H][C@@]12CN(C(=O)/C=C/C3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.[H][C@@]12CN(C(=O)/C=C/C3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] LIJZSSLYOCZDLT-KJKCOSIVSA-N 0.000 description 1
- XBLAMWHOKWECGS-FWEDZOCSSA-N *.[H][C@@]12CN(C(=O)C3=CC4=C(C=C(OC(F)(F)F)C=C4)N3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.[H][C@@]12CN(C(=O)C3=CC4=C(C=C(OC(F)(F)F)C=C4)N3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] XBLAMWHOKWECGS-FWEDZOCSSA-N 0.000 description 1
- OCHLKROUZWKHBS-UWLPGLTFSA-N *.[H][C@@]12CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] Chemical compound *.[H][C@@]12CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3)C[C@]1([H])[C@@]1([H])CN(C(=O)[C@@H]3CCC4=C(C3)N=NN4)C[C@@]21[H] OCHLKROUZWKHBS-UWLPGLTFSA-N 0.000 description 1
- GJMMGIIGKYUMIY-UHFFFAOYSA-N C1=CC=C(CN2CC3C(C2)C2CN(CC4=CC=CC=C4)CC32)C=C1.C1NCC2C1C1CNCC21.O=C1C2C(C(=O)N1CC1=CC=CC=C1)C1C(=O)N(CC3=CC=CC=C3)C(=O)C21.O=C1C=CC(=O)N1CC1=CC=CC=C1.O=C1C=CC(=O)N1CC1=CC=CC=C1 Chemical compound C1=CC=C(CN2CC3C(C2)C2CN(CC4=CC=CC=C4)CC32)C=C1.C1NCC2C1C1CNCC21.O=C1C2C(C(=O)N1CC1=CC=CC=C1)C1C(=O)N(CC3=CC=CC=C3)C(=O)C21.O=C1C=CC(=O)N1CC1=CC=CC=C1.O=C1C=CC(=O)N1CC1=CC=CC=C1 GJMMGIIGKYUMIY-UHFFFAOYSA-N 0.000 description 1
- FKYWLZUPBICXFW-UHFFFAOYSA-N C1NCC2C1C1CNCC21 Chemical compound C1NCC2C1C1CNCC21 FKYWLZUPBICXFW-UHFFFAOYSA-N 0.000 description 1
- SJMIQGSZTCGLTG-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC2C(C1)C1CN(C(=O)OC(C)(C)C)CC21 Chemical compound CC(C)(C)OC(=O)N1CC2C(C1)C1CN(C(=O)OC(C)(C)C)CC21 SJMIQGSZTCGLTG-UHFFFAOYSA-N 0.000 description 1
- FEQHHCSGTCYXEC-UHFFFAOYSA-N CC(C)(C)OC(=O)N1CC2C3CNCC3C2C1 Chemical compound CC(C)(C)OC(=O)N1CC2C3CNCC3C2C1 FEQHHCSGTCYXEC-UHFFFAOYSA-N 0.000 description 1
- MDMTXUJVUZMVBG-ZCQNZVIGSA-N [H][C@@]12CN(C(=O)C3=CC4=C(C=C3)NN=N4)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C(=O)C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC4=C(C=C3)NN=N4)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C(=O)C3)C[C@@]21[H] MDMTXUJVUZMVBG-ZCQNZVIGSA-N 0.000 description 1
- FVIGPGZCUVTOKV-ZDNVTZCJSA-N [H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] FVIGPGZCUVTOKV-ZDNVTZCJSA-N 0.000 description 1
- DASWAIJAFJYOIT-ZYGGUILKSA-N [H][C@@]12CN(C(=O)C3=CC=C(OCC(F)(F)F)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C(OCC(F)(F)F)N=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] DASWAIJAFJYOIT-ZYGGUILKSA-N 0.000 description 1
- GWEHZCYNPKYJHH-SEXKYXSUSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC4=C(C=C3)NC=C4)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC4=C(C=C3)NC=C4)C[C@@]21[H] GWEHZCYNPKYJHH-SEXKYXSUSA-N 0.000 description 1
- UCSZLTVMEILRKY-ZDNVTZCJSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4C(=C3)NC3=C4C=C(Cl)C=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4C(=C3)NC3=C4C=C(Cl)C=C3)C[C@@]21[H] UCSZLTVMEILRKY-ZDNVTZCJSA-N 0.000 description 1
- IWHHORGPOYYCIN-SEXKYXSUSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4C=CNC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4C=CNC4=C3)C[C@@]21[H] IWHHORGPOYYCIN-SEXKYXSUSA-N 0.000 description 1
- YQGXRLRMBSHZBB-RWRHNGIRSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC(=O)C4=C(C=CC=C4)C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC(=O)C4=C(C=CC=C4)C3)C[C@@]21[H] YQGXRLRMBSHZBB-RWRHNGIRSA-N 0.000 description 1
- WSCYDTOBUCGZDR-UKVZOCTBSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC4=C(C=CC=C4)C(C)(C)C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CC4=C(C=CC=C4)C(C)(C)C3)C[C@@]21[H] WSCYDTOBUCGZDR-UKVZOCTBSA-N 0.000 description 1
- VVQPZHLACQBXAJ-JIABUMJYSA-N [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CCC4=C(C=CC=C4)C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3CCC4=C(C=CC=C4)C3)C[C@@]21[H] VVQPZHLACQBXAJ-JIABUMJYSA-N 0.000 description 1
- USLNSMSYKNTRSA-UJOPUZHASA-N [H][C@@]12CN(C(=O)COC3=C(C(C)C)C=CC=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)COC3=C(C(C)C)C=CC=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] USLNSMSYKNTRSA-UJOPUZHASA-N 0.000 description 1
- SGXAQPMGUSKRHW-SEXKYXSUSA-N [H][C@@]12CN(C(=O)COC3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)COC3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] SGXAQPMGUSKRHW-SEXKYXSUSA-N 0.000 description 1
- IQRGXRSRUQQAAD-SEXKYXSUSA-N [H][C@@]12CN(C(=O)OCC3=CC(Cl)=CC(Cl)=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=C/C=C4/NN=N/C4=C\3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)OCC3=CC(Cl)=CC(Cl)=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=C/C=C4/NN=N/C4=C\3)C[C@@]21[H] IQRGXRSRUQQAAD-SEXKYXSUSA-N 0.000 description 1
- KQGJFNOAZQYCQN-SEXKYXSUSA-N [H][C@@]12CN(C(=O)OCC3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] Chemical compound [H][C@@]12CN(C(=O)OCC3=CC=C(OC(F)(F)F)C=C3)C[C@]1([H])[C@@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]21[H] KQGJFNOAZQYCQN-SEXKYXSUSA-N 0.000 description 1
- RNTVVANWEGFYEA-FQNXGMEXSA-N [H][C@]12CN(C(=O)/C=C/C3=CC=C(OC(F)(F)F)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)/C=C/C3=CC=C(OC(F)(F)F)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] RNTVVANWEGFYEA-FQNXGMEXSA-N 0.000 description 1
- NSHUGUYQKIEWIE-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=C/C=C4\NN=N\C4=C\3)C[C@@]1([H])[C@]1([H])CN(S(=O)(=O)C3=CC=C4C=C(Cl)C=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=C/C=C4\NN=N\C4=C\3)C[C@@]1([H])[C@]1([H])CN(S(=O)(=O)C3=CC=C4C=C(Cl)C=CC4=C3)C[C@]21[H] NSHUGUYQKIEWIE-ZDNVTZCJSA-N 0.000 description 1
- UIAIQXDECLHLDE-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC(OCC)=C4C=C(C(F)(F)F)C=CC4=N3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC(OCC)=C4C=C(C(F)(F)F)C=CC4=N3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=N3)C[C@]21[H] UIAIQXDECLHLDE-FZDBZEDMSA-N 0.000 description 1
- OCIMWOSKBJPSJX-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC4=C(C=C3)NN=N4)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC4=C(C=C3)NN=N4)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@]21[H] OCIMWOSKBJPSJX-ZDNVTZCJSA-N 0.000 description 1
- GYLZFOZVMJOEBB-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C(C4=CC=C(Cl)C=C4)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] GYLZFOZVMJOEBB-NVPYSNMXSA-N 0.000 description 1
- QTIDKZNWTMKRLS-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] QTIDKZNWTMKRLS-NVPYSNMXSA-N 0.000 description 1
- GRBNDKYFGFDJSC-FATVKVNYSA-N [H][C@]12CN(C(=O)C3=CC=C(S(N)(=O)=O)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C(S(N)(=O)=O)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]21[H] GRBNDKYFGFDJSC-FATVKVNYSA-N 0.000 description 1
- VLNJAZOILNVBBF-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(Br)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(Br)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] VLNJAZOILNVBBF-ZDNVTZCJSA-N 0.000 description 1
- HUZKLTBYUZHDOT-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(C#N)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(C#N)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] HUZKLTBYUZHDOT-ZCQNZVIGSA-N 0.000 description 1
- BBNLYXWJYWQSSH-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(C)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(C)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] BBNLYXWJYWQSSH-ZCQNZVIGSA-N 0.000 description 1
- GDRCZHGYAGHZNZ-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(Cl)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C/C=C4/NN=N/C4=C\3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(Cl)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C/C=C4/NN=N/C4=C\3)C[C@]21[H] GDRCZHGYAGHZNZ-ZDNVTZCJSA-N 0.000 description 1
- NDJMULRYFGBCKA-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4C=C(OC)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=C(OC)C=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] NDJMULRYFGBCKA-ZCQNZVIGSA-N 0.000 description 1
- ZTTSLCPCMVQKSR-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4C=CC(C)=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=CC(C)=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] ZTTSLCPCMVQKSR-ZCQNZVIGSA-N 0.000 description 1
- CMPWWWUAGTWRJS-KXSOJQAOSA-N [H][C@]12CN(C(=O)C3=CC=C4C=CC(C5=CC=CC=C5)=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=CC(C5=CC=CC=C5)=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] CMPWWWUAGTWRJS-KXSOJQAOSA-N 0.000 description 1
- WPDAFIWSRIGEKD-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4C=CC=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4C=CC=CC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] WPDAFIWSRIGEKD-ZDNVTZCJSA-N 0.000 description 1
- ITAQKBVXORDFBT-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4CCCCC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4CCCCC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] ITAQKBVXORDFBT-ZDNVTZCJSA-N 0.000 description 1
- OLMRJUURGFNAIF-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(OC)C=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=C(OC)C=C4C=CC=CC4=C3)C[C@]21[H] OLMRJUURGFNAIF-ZDNVTZCJSA-N 0.000 description 1
- BNQXTLWINPFFNL-SYMSYNOKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(Br)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(Br)=C(OCC(F)(F)F)N=C3)C[C@]21[H] BNQXTLWINPFFNL-SYMSYNOKSA-N 0.000 description 1
- RVSHWVZFEATTLW-ZYGGUILKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(Br)=C(OCC(F)(F)F)N=C3C)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(Br)=C(OCC(F)(F)F)N=C3C)C[C@]21[H] RVSHWVZFEATTLW-ZYGGUILKSA-N 0.000 description 1
- AWKRIUAQQWCVQT-SYMSYNOKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C(F)(F)F)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C(F)(F)F)=C(OCC(F)(F)F)N=C3)C[C@]21[H] AWKRIUAQQWCVQT-SYMSYNOKSA-N 0.000 description 1
- WWCDQTZRSVNTRI-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C)=C4C=CC=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C)=C4C=CC=CC4=N3)C[C@]21[H] WWCDQTZRSVNTRI-JVSBHGNQSA-N 0.000 description 1
- FKOBWPARARYMIQ-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4=CC=C(Cl)C=C4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4=CC=C(Cl)C=C4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] FKOBWPARARYMIQ-ZCQNZVIGSA-N 0.000 description 1
- GKDFABQRNAFECM-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4=CC=CO4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4=CC=CO4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] GKDFABQRNAFECM-JVSBHGNQSA-N 0.000 description 1
- ODUJWCLJMROQME-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4CC4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4CC4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] ODUJWCLJMROQME-JVSBHGNQSA-N 0.000 description 1
- ONYNKDLJGOXVKM-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4CCOCC4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(C4CCOCC4)=C(OCC(F)(F)F)N=C3)C[C@]21[H] ONYNKDLJGOXVKM-ZDNVTZCJSA-N 0.000 description 1
- ISNUPUVCKIHHCL-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4C=CC=CC4=C3)C[C@]21[H] ISNUPUVCKIHHCL-NVPYSNMXSA-N 0.000 description 1
- BKXBVEDCBTULQH-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4CCCCC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC(C)C)=C4CCCCC4=C3)C[C@]21[H] BKXBVEDCBTULQH-NVPYSNMXSA-N 0.000 description 1
- CJZJFGVPYXRIEF-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=C4C=CC=CC4=C3)C[C@]21[H] CJZJFGVPYXRIEF-ZDNVTZCJSA-N 0.000 description 1
- BPEHKFDIYGQATM-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=C4C=CC=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OC)=C4C=CC=CC4=N3)C[C@]21[H] BPEHKFDIYGQATM-SEXKYXSUSA-N 0.000 description 1
- BVHRASPCRVYCKL-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C(C4CC4)C=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C(C4CC4)C=N3)C[C@]21[H] BVHRASPCRVYCKL-SEXKYXSUSA-N 0.000 description 1
- JJKOUNLIHXOCRM-ZYGGUILKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C(C4CC4)N=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC(F)(F)F)=C(C4CC4)N=N3)C[C@]21[H] JJKOUNLIHXOCRM-ZYGGUILKSA-N 0.000 description 1
- CONRAFWALCETHT-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=C(C(F)(F)F)C=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=C(C(F)(F)F)C=CC4=N3)C[C@]21[H] CONRAFWALCETHT-JVSBHGNQSA-N 0.000 description 1
- QCKGVCQULXMWKW-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC=CC4=C3)C[C@]21[H] QCKGVCQULXMWKW-ZCQNZVIGSA-N 0.000 description 1
- LVWMSLXMWQERMW-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CN(CC(F)(F)F)C4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CN(CC(F)(F)F)C4=C3)C[C@]21[H] LVWMSLXMWQERMW-UJOPUZHASA-N 0.000 description 1
- KXLCIXWJASBLBZ-UCDDGIFISA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC4CC4)=C4C=CC=CC4=C3)C[C@]21[H] KXLCIXWJASBLBZ-UCDDGIFISA-N 0.000 description 1
- RNDNEOAXPINSQK-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCCOC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCCOC)=C4C=CC=CC4=C3)C[C@]21[H] RNDNEOAXPINSQK-NVPYSNMXSA-N 0.000 description 1
- CTUNKEKEWVCZDC-ZYGGUILKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(S(C)(=O)=O)=C(OCC(F)(F)F)N=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(S(C)(=O)=O)=C(OCC(F)(F)F)N=C3)C[C@]21[H] CTUNKEKEWVCZDC-ZYGGUILKSA-N 0.000 description 1
- ONLMPHGQIJGDBY-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(C)C=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(C)C=C4)N3)C[C@]21[H] ONLMPHGQIJGDBY-SEXKYXSUSA-N 0.000 description 1
- BRNMFQSSCQBSOW-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(Cl)C=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(Cl)C=C4)N3)C[C@]21[H] BRNMFQSSCQBSOW-FZDBZEDMSA-N 0.000 description 1
- MSURHAZYRUGXEI-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(Cl)C=C4)N3C)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(Cl)C=C4)N3C)C[C@]21[H] MSURHAZYRUGXEI-SEXKYXSUSA-N 0.000 description 1
- SDLLPMFIYVHHSA-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(OC(F)(F)F)C=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=C(OC(F)(F)F)C=C4)N3)C[C@]21[H] SDLLPMFIYVHHSA-FZDBZEDMSA-N 0.000 description 1
- RZIPUTXFMKCUGO-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(C#N)=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(C#N)=C4)N3)C[C@]21[H] RZIPUTXFMKCUGO-SEXKYXSUSA-N 0.000 description 1
- KHWXTUHDUYUMQU-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(Cl)=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(Cl)=C4)N3)C[C@]21[H] KHWXTUHDUYUMQU-FZDBZEDMSA-N 0.000 description 1
- VKCLGKWQSRLJIS-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3)C[C@]21[H] VKCLGKWQSRLJIS-FZDBZEDMSA-N 0.000 description 1
- YPMDJJQEXWALBJ-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3C)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC(OC(F)(F)F)=C4)N3C)C[C@]21[H] YPMDJJQEXWALBJ-SEXKYXSUSA-N 0.000 description 1
- WQFQCQTXDBIXNV-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC4)C(OC(C)C)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC4)C(OC(C)C)=C3)C[C@]21[H] WQFQCQTXDBIXNV-ZCQNZVIGSA-N 0.000 description 1
- SZIIJIBEMMWNIR-KNJLRNSFSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC4)C(OCC4=CC=CC=C4)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC4)C(OCC4=CC=CC=C4)=C3)C[C@]21[H] SZIIJIBEMMWNIR-KNJLRNSFSA-N 0.000 description 1
- ZHGOJIZONMIABO-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3)C[C@]21[H] ZHGOJIZONMIABO-FZDBZEDMSA-N 0.000 description 1
- ZXOBJHJBYQOJSP-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3C)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3C)C[C@]21[H] ZXOBJHJBYQOJSP-SEXKYXSUSA-N 0.000 description 1
- ORTIIGWDRAGIOC-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3CC#N)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3CC#N)C[C@]21[H] ORTIIGWDRAGIOC-JVSBHGNQSA-N 0.000 description 1
- XXHPMFDGAXUBSO-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3CC(C)C)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CC=C4)N3CC(C)C)C[C@]21[H] XXHPMFDGAXUBSO-ZDNVTZCJSA-N 0.000 description 1
- PFGVGCJEZPRXSL-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CN4C)C(OC(C)C)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CN4C)C(OC(C)C)=C3)C[C@]21[H] PFGVGCJEZPRXSL-ZDNVTZCJSA-N 0.000 description 1
- ILIIVOLVKCQDFT-ZCQNZVIGSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CN4CC)C(OC(C)C)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=C(C=CN4CC)C(OC(C)C)=C3)C[C@]21[H] ILIIVOLVKCQDFT-ZCQNZVIGSA-N 0.000 description 1
- NDJOMJCRJYWLRJ-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=CC=CC=C4C(OCC)=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC4=CC=CC=C4C(OCC)=N3)C[C@]21[H] NDJOMJCRJYWLRJ-UJOPUZHASA-N 0.000 description 1
- PAAGLCNHJLTGIL-ZYGGUILKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C(OCC(F)(F)F)C=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C(OCC(F)(F)F)C=N3)C[C@]21[H] PAAGLCNHJLTGIL-ZYGGUILKSA-N 0.000 description 1
- OLKTYPHAYCAQBM-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C(OCC4CC4)N=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C(OCC4CC4)N=N3)C[C@]21[H] OLKTYPHAYCAQBM-FZDBZEDMSA-N 0.000 description 1
- QMZXSFKYNKKFAF-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4C=CC=CC4=C3OC)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4C=CC=CC4=C3OC)C[C@]21[H] QMZXSFKYNKKFAF-ZDNVTZCJSA-N 0.000 description 1
- HZGSRAKFUJASPU-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4C=CC=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4C=CC=CC4=N3)C[C@]21[H] HZGSRAKFUJASPU-SEXKYXSUSA-N 0.000 description 1
- ZBUCIYKGJCCIEP-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OC)=C4C=CC=CC4=C3)C[C@]21[H] ZBUCIYKGJCCIEP-JVSBHGNQSA-N 0.000 description 1
- BLRRNEURDDOODU-PYHGIMPFSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=C(C(F)(F)F)C=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=C(C(F)(F)F)C=C3)C[C@]21[H] BLRRNEURDDOODU-PYHGIMPFSA-N 0.000 description 1
- SVMYVCAWPRQJHP-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=C4C=CC=CC4=C3)C[C@]21[H] SVMYVCAWPRQJHP-JVSBHGNQSA-N 0.000 description 1
- RMGHRCUXBWTBOQ-SYMSYNOKSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=CC=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC(F)(F)F)=CC=C3)C[C@]21[H] RMGHRCUXBWTBOQ-SYMSYNOKSA-N 0.000 description 1
- WXCFARDGANJOFV-FZDBZEDMSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C(C(F)(F)F)C=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C(C(F)(F)F)C=C3)C[C@]21[H] WXCFARDGANJOFV-FZDBZEDMSA-N 0.000 description 1
- DBRWJWIKNXFOGS-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C(C4CC4)C=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC4CC4)=C(C4CC4)C=C3)C[C@]21[H] DBRWJWIKNXFOGS-ZDNVTZCJSA-N 0.000 description 1
- GUNUMIZPGOXINK-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCCOC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCCOC)=C4C=CC=CC4=C3)C[C@]21[H] GUNUMIZPGOXINK-ZDNVTZCJSA-N 0.000 description 1
- WNEVLGBTEUPPDW-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=C(CCCC4)C(OCC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=C(CCCC4)C(OCC)=C3)C[C@]21[H] WNEVLGBTEUPPDW-JVSBHGNQSA-N 0.000 description 1
- OKKWEBFRVXIREA-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(C(F)(F)F)=CC=C4C(OCCOC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC(C(F)(F)F)=CC=C4C(OCCOC)=C3)C[C@]21[H] OKKWEBFRVXIREA-UJOPUZHASA-N 0.000 description 1
- RAVQDUYJMPKWTB-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=C(Cl)C=C4C(OCC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=C(Cl)C=C4C(OCC)=C3)C[C@]21[H] RAVQDUYJMPKWTB-JVSBHGNQSA-N 0.000 description 1
- XIWDJEBYKWOMKH-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OC(C)C)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OC(C)C)=C3)C[C@]21[H] XIWDJEBYKWOMKH-UJOPUZHASA-N 0.000 description 1
- VYYHSKRKZLPSMH-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC)=C3)C[C@]21[H] VYYHSKRKZLPSMH-JVSBHGNQSA-N 0.000 description 1
- BEGYRDCBDAEONM-ZDNVTZCJSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC4CC4)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCC4CC4)=C3)C[C@]21[H] BEGYRDCBDAEONM-ZDNVTZCJSA-N 0.000 description 1
- VIHUOEBIQGAKKA-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCCOC)=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC4=CC=CC=C4C(OCCOC)=C3)C[C@]21[H] VIHUOEBIQGAKKA-UJOPUZHASA-N 0.000 description 1
- XYZGMMPZUOFWFM-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC=C4C=CC=CC4=C3)C[C@]21[H] XYZGMMPZUOFWFM-JVSBHGNQSA-N 0.000 description 1
- GPCGTTBANIZMHS-AEJJZOKQSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3CCC4=C(C=CC=C4)O3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3CCC4=C(C=CC=C4)O3)C[C@]21[H] GPCGTTBANIZMHS-AEJJZOKQSA-N 0.000 description 1
- DEZGHYZZFUJVJV-UJOPUZHASA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)N3CCC4=C(C=CC(C(F)(F)F)=C4)C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)N3CCC4=C(C=CC(C(F)(F)F)=C4)C3)C[C@]21[H] DEZGHYZZFUJVJV-UJOPUZHASA-N 0.000 description 1
- ZHJHRDNVYMOTMS-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(S(=O)(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@@]1([H])[C@]1([H])CN(S(=O)(=O)C3=CC=C(C4=CC=C(F)C=C4)C=C3)C[C@]21[H] ZHJHRDNVYMOTMS-NVPYSNMXSA-N 0.000 description 1
- HNSNTEASMWFQEO-SEXKYXSUSA-N [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=N3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC)=C4C=CC=CC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=C4NN=NC4=N3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=NC(OCC)=C4C=CC=CC4=C3)C[C@]21[H] HNSNTEASMWFQEO-SEXKYXSUSA-N 0.000 description 1
- MIMPOCUBMLHQOI-NVPYSNMXSA-N [H][C@]12CN(C(=O)C3=CC=CC(C4=CC=C(Cl)C=C4)=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CC=CC(C4=CC=C(Cl)C=C4)=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] MIMPOCUBMLHQOI-NVPYSNMXSA-N 0.000 description 1
- JLGVTJLSBBVSIV-JVSBHGNQSA-N [H][C@]12CN(C(=O)C3=CN=C(S(N)(=O)=O)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC=CC4=N3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)C3=CN=C(S(N)(=O)=O)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC(OCC)=C4C=CC=CC4=N3)C[C@]21[H] JLGVTJLSBBVSIV-JVSBHGNQSA-N 0.000 description 1
- ATNZOJLZHRMSQE-JVSBHGNQSA-N [H][C@]12CN(C(=O)CCC3=CC=C(OC(F)(F)F)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] Chemical compound [H][C@]12CN(C(=O)CCC3=CC=C(OC(F)(F)F)C=C3)C[C@@]1([H])[C@]1([H])CN(C(=O)C3=CC=C4NN=NC4=C3)C[C@]21[H] ATNZOJLZHRMSQE-JVSBHGNQSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the present invention relates to organic compounds useful for therapy or prophylaxis in a mammal, and in particular to autotaxin (ATX) inhibitors which are inhibitors of lysophosphatidic acid (LPA) production and thus modulators of LPA levels and associated signaling, for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
- ATX autotaxin
- LPA lysophosphatidic acid
- the present invention provides novel compounds of formula (I)
- ATX Autotaxin
- LPC lysophosphatidyl choline
- LPA bioactive signaling molecule lysophosphatidic acid
- LPA can elicit a wide range of cellular responses; including smooth muscle cell contraction, platelet activation, cell proliferation, chemotaxis and others.
- LPA mediates its effects via signaling to several G protein coupled receptors (GPCRs); the first members were originally denoted Edg (endothelial cell differentiation gene) receptors or ventricular zone gene-1 (vzg-1) but are now called LPA receptors.
- GPCRs G protein coupled receptors
- Edg endothelial cell differentiation gene
- vzg-1 ventricular zone gene-1
- the prototypic group now consists of LPA1/Edg-2/VZG-1, LPA2/Edg-4, and LPA3/Edg-7.
- the ATX-LPA signaling axis is involved in a large range of physiological and pathophysiological functions, including, for example, nervous system function, vascular development, cardiovascular physiology, reproduction, immune system function, chronic inflammation, tumor metastasis and progression, organ fibrosis as well as obesity and/or other metabolic diseases such as diabetes mellitus. Therefore, increased activity of ATX and/or increased levels of LPA, altered LPA receptor expression and altered responses to LPA may contribute to the initiation, progression and/or outcome of a number of different pathophysiological conditions related to the ATX/LPA axis.
- the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of diseases, disorders or conditions that are associated with the activity of autotaxin and/or the biological activity of lysophosphatidic acid (LPA).
- LPA lysophosphatidic acid
- the compounds of formula (I) or their pharmaceutically acceptable salts and esters herein inhibit autotaxin activity and therefore inhibit LPA production and modulate LPA levels and associated signaling.
- Autotaxin inhibitors described herein are useful as agents for the treatment or prevention of diseases or conditions in which ATX activity and/or LPA signaling participates, is involved in the etiology or pathology of the disease, or is otherwise associated with at least one symptom of the disease.
- the ATX-LPA axis has been implicated for example in angiogenesis, chronic inflammation, autoimmune diseases, fibrotic diseases, cancer and tumor metastasis and progression, ocular conditions, metabolic conditions such as obesity and/or diabetes mellitus, conditions such as cholestatic or other forms of chronic pruritus as well as acute and chronic organ transplant rejection.
- Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of disorders or conditions that are associated with the activity of ATX and/or the biological activity of lysophosphatidic acid (LPA), particularly in the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and-chronic organ transplant rejection, and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and
- alkenyl denotes a monovalent linear or branched hydrocarbon group of 2 to 7 carbon atoms with at least one double bond. In particular embodiments, alkenyl has 2 to 4 carbon atoms with at least one double bond. Examples of alkenyl include ethenyl, propenyl, prop-2-enyl, isopropenyl, n-butenyl and iso-butenyl. Particular alkenyl group is ethenyl.
- alkoxy denotes a group of the formula —O—R′, wherein R′ is an alkyl group.
- alkoxy group include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy and tert-butoxy.
- Particular alkoxy group include methoxy, ethoxy and isopropoxy. More particular alkoxy group is isopropoxy.
- alkoxyalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by another alkoxy group.
- alkoxyalkoxy group examples include methoxymethoxy, ethoxymethoxy, methoxyethoxy, ethoxyethoxy, methoxypropoxy and ethoxypropoxy.
- Particular alkoxyalkoxy group is methoxyethoxy.
- alkoxyalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an alkoxyalkoxy group.
- alkoxyalkoxyalkyl group include methoxymethoxymethyl, ethoxymethoxymethyl, methoxyethoxymethyl, ethoxyethoxymethyl, methoxypropoxymethyl, ethoxypropoxymethyl, methoxymethoxyethyl, ethoxymethoxyethyl, methoxyethoxyethyl, ethoxyethoxyethyl, methoxypropoxyethyl and ethoxypropoxyethyl.
- alkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by an alkoxy group.
- alkoxyalkyl groups include methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl, methoxypropyl, ethoxypropyl and isopropoxymethyl.
- Particular alkoxyalkyl group is methoxpropyl.
- alkoxyhaloalkyl denotes a haloalkyl group wherein at least one of the hydrogen atoms of the haloalkyl group has been replaced by an alkoxy group.
- alkoxyalkyl groups include methoxytrifluoroethyl, ethoxytrifluoroethyl, methoxytrifluoropropyl and ethoxytrifluoropropyl.
- alkyl denotes a monovalent linear or branched saturated hydrocarbon group of 1 to 12 carbon atoms. In particular embodiments, alkyl has 1 to 7 carbon atoms, and in more particular embodiments 1 to 4 carbon atoms. Examples of alkyl include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl and sec-butyl, pentyl. Particular alkyl groups include methyl, isopropyl and iso-butyl.
- alkylsulfonyl denotes a group of the formula —S(O) 2 —R′, wherein R′ is an alkyl group.
- alkylsulfonyl groups include groups of the formula —S(O) 2 —R′, wherein R′ is methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl.
- Particular alkylsulfonyl groups include group of the formula —S(O) 2 —R′, wherein R′ is methyl.
- amino denotes a —NH 2 group.
- aminosulfonyl denotes a —S(O) 2 —NH 2 group.
- cyano denotes a —C ⁇ N group.
- cyanoalkyl denotes an alkyl group wherein one of the hydrogen atoms of the alkyl group has been replaced by a cyano group.
- exemplary cyanoalkyl groups include cyanomethyl, cyanoethyl and cyanopropyl.
- Particular alkoxyalkyl group is cyanomethyl.
- cycloalkoxy denotes a group of the formula —O—R′, wherein R′ is a cycloalkyl group.
- examples of cycloalkoxy group include cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy and cyclooctyloxy.
- Particular cycloalkoxy group is cyclopropoxy.
- cycloalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a cycloalkoxy group.
- cycloalkoxyalkyl groups include cyclopropoxymethyl, cyclopropoxyethyl, cyclobutoxymethyl, cyclobutoxyethyl, cyclopentyloxymethyl, cyclopentyloxyethyl, cyclohexyloxymethyl, cyclohexyloxyethyl, cycloheptyloxymethyl, cycloheptyloxyethyl, cyclooctyloxymethyl and cyclooctyloxyethyl.
- cycloalkyl denotes a monovalent saturated monocyclic or bicyclic hydrocarbon group of 3 to 10 ring carbon atoms.
- cycloalkyl denotes a monovalent saturated monocyclic hydrocarbon group of 3 to 8 ring carbon atoms.
- Bicyclic means a ring system consisting of two saturated carbocycles having two carbon atoms in common.
- monocyclic cycloalkyl are cyclopropyl, cyclobutanyl, cyclopentyl, cyclohexyl or cycloheptyl.
- bicyclic cycloalkyl are bicyclo[2.2.1]heptanyl or bicyclo[2.2.2]octanyl.
- Particular monocyclic cycloalkyl groups are cyclopropyl, cyclobutanyl, cyclopentyl and cyclohexyl. More particular monocyclic cycloalkyl group is cyclopropyl.
- cycloalkylalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group is replaced by a cycloalkyl group.
- examples of cycloalkylalkoxy include cyclopropylmethoxy, cyclobutylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, cycloheptylmethoxy and cyclooctylmethoxy.
- Particular cycloalkylalkoxy group is cyclopropylmethoxy.
- cycloalkylalkoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cycloalkylalkoxy group.
- cycloalkylalkoxyalkyl include cyclopropylmethoxymethyl, cyclopropylmethoxyethyl, cyclobutylmethoxymethyl, cyclobutylmethoxyethyl, cyclopentylmethoxyethyl, cyclopentylmethoxyethyl, cyclohexylmethoxymethyl, cyclohexylmethoxyethyl, cycloheptylmethoxymethyl, cycloheptylmethoxyethyl, cyclooctylmethoxymethyl and cyclooctylmethoxyethyl.
- cycloalkylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group is replaced by a cycloalkyl group.
- examples of cycloalkylalkyl include cyclopropylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylpropyl, 2-cyclopropylbutyl, cyclopentylbutyl, cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[4.1.0]heptanylethyl, bicyclo[2.2.2]octanylmethyl, bicyclo[2.2.2]octanylethyl, adamentanylmethyl and adamantanylethyl.
- cycloalkylalkyl are cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[4.1.0]heptanylethyl, bicyclo[2.2.2]octanylmethyl, bicyclo[2.2.2]octanylethyl, adamentanylmethyl and adamantanylethyl.
- cycloalkylalkyl are cyclohexylmethyl, cyclohexylethyl, bicyclo[4.1.0]heptanylmethyl, bicyclo[2.2.2]octanylmethyl, adamentanylmethyl and adamantanylethyl.
- haloalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by the same or different halogen atoms.
- perhaloalkoxy denotes an alkoxy group where all hydrogen atoms of the alkoxy group have been replaced by the same or different halogen atoms.
- haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, trifluoroethoxy, trifluoromethylethoxy, trifluorodimethylethoxy and pentafluoroethoxy.
- Particular haloalkoxy group are trifluoromethoxy and trifluoroethoxy.
- haloalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by the same or different halogen atoms.
- perhaloalkyl denotes an alkyl group where all hydrogen atoms of the alkyl group have been replaced by the same or different halogen atoms. Examples of haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, trifluoromethylethyl and pentafluoroethyl. Particular haloalkyl groups are trifluoromethyl and trifluoroethyl.
- halogen and “halo” are used interchangeably herein and denote fluoro, chloro, bromo, or iodo. Particular halogens are chloro and fluoro. More particular halogen is chloro.
- hydroxy denotes a —OH group.
- hydroxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a hydroxy group.
- examples of hydroxyalkyl include hydroxymethyl, hydroxyethyl, hydroxy-1-methyl-ethyl, hydroxypropyl, hydroxymethylpropyl and dihydroxypropyl. Particular examples are hydroxymethyl and hydroxyethyl.
- hydroxyhaloalkyl denotes a haloalkyl group wherein at least one of the hydrogen atoms of the haloalkyl group has been replaced by an hydroxy group.
- exemplary hydroxyhaloalkyl groups include hydroxytrifluoroethyl and hydroxytrifluoropropyl.
- Particular hydroxyhaloalkyl groups include hydroxytrifluoroethyl.
- phenoxy denotes a group of the formula —O—R′, wherein R′ is a phenyl.
- phenoxyalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced by a phenoxy group.
- exemplary phenoxyalkyl groups include phenoxymethyl, phenoxyethyl and phenoxypropyl.
- Particular alkoxyalkyl group is phenoxymethyl.
- phenylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a phenyl.
- Particular phenylalkenyl group is phenylethenyl.
- phenylalkoxy denotes an alkoxy group wherein at least one of the hydrogen atoms of the alkoxy group has been replaced by a phenyl group.
- phenylalkoxy include phenylmethoxy and phenylethoxy.
- Particular phenylalkoxy group is phenylmethoxy.
- phenylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a phenyl.
- Particular phenylalkyl groups are benzyl, phenethyl and phenylpropyl. More particular phenylalkyl groups are benzyl and phenethyl. Further particular phenylalkyl group is benzyl.
- phenylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a phenyl. Particular phenylalkynyl group is phenylethynyl.
- phenylcyloalkyl denotes a cycloalkyl group wherein at least one of the hydrogen atoms of the cycloalkyl group has been replaced a phenyl.
- Particular phenylcycloalkyl group is phenylcyclopropyl.
- pyridazinylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a pyridazinyl.
- Particular pyridazinylalkenyl group is pyridazinylethenyl.
- pyridazinylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a pyridazinyl.
- Particular pyridazinylalkyl groups are pyridazinylmethyl, pyridazinylethyl and pyridazinylpropyl. More particular pyridazinylalkyl group is pyridazinylethyl.
- pyridazinylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a pyridazinyl.
- Particular pyridazinylalkynyl group is pyridazinylethynyl.
- pyridinonylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a pyridinonyl.
- Particular pyridinonylalkenyl group is pyridinonylethenyl.
- pyridinonylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a pyridinonyl.
- Particular pyridinonylalkyl groups are pyridinonylmethyl, pyridinonylethyl and pyridinonylpropyl. More particular pyridinonylalkyl group is pyridinonylethyl.
- pyridinonyl alkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a pyridinonyl.
- Particular pyridinonyl alkynyl group is pyridinonylethynyl.
- pyridinylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a pyridinyl.
- Particular pyridinylalkenyl group is pyridinylethenyl.
- pyridinylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a pyridinyl.
- Particular pyridinylalkyl groups are pyridinylmethyl, pyridinylethyl and pyridinylpropyl. More particular pyridinylalkyl group is pyridinylethyl.
- pyridinylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a pyridinyl.
- Particular pyridinylalkynyl group is pyridinylethynyl.
- thiophenylalkenyl denotes an alkenyl group wherein at least one of the hydrogen atoms of the alkenyl group has been replaced a thiophenyl. Particular thiophenylalkenyl group is thiophenylethenyl.
- thiophenylalkyl denotes an alkyl group wherein at least one of the hydrogen atoms of the alkyl group has been replaced a thiophenyl.
- Particular thiophenylalkyl groups are thiophenylmethyl, thiophenylethyl and thiophenylpropyl. More particular thiophenylalkyl group is thiophenylmethyl.
- thiophenylalkynyl denotes an alkynyl group wherein at least one of the hydrogen atoms of the alkynyl group has been replaced a thiophenyl. Particular thiophenylalkynyl group is thiophenylethynyl.
- salts refers to those salts which retain the biological effectiveness and properties of the free bases or free acids, which are not biologically or otherwise undesirable.
- the salts are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, in particular hydrochloric acid, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, N-acetylcystein and the like.
- salts may be prepared by addition of an inorganic base or an organic base to the free acid.
- Salts derived from an inorganic base include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium salts and the like.
- Salts derived from organic bases include, but are not limited to salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, lysine, arginine, N-ethylpiperidine, piperidine, polyimine resins and the like.
- Particular pharmaceutically acceptable salts of compounds of formula (I) are the sodium and potassium salts.
- “Pharmaceutically acceptable esters” means that compounds of general formula (I) may be derivatised at functional groups to provide derivatives which are capable of conversion back to the parent compounds in vivo. Examples of such compounds include physiologically acceptable and metabolically labile ester derivatives, such as methoxymethyl esters, methylthiomethyl esters and pivaloyloxymethyl esters. Additionally, any physiologically acceptable equivalents of the compounds of general formula (I), similar to the metabolically labile esters, which are capable of producing the parent compounds of general formula (I) in vivo, are within the scope of this invention.
- protecting group denotes a group which selectively blocks a reactive site in a multifunctional compound such that a chemical reaction can be carried out selectively at another unprotected reactive site in the meaning conventionally associated with it in synthetic chemistry.
- Protecting groups can be removed at the appropriate point.
- Exemplary protecting groups are amino-protecting groups, carboxy-protecting groups or hydroxy-protecting groups.
- Particular protecting groups are the tert-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), fluorenylmethoxycarbonyl (Fmoc) and benzyl (Bn) groups.
- Further particular protecting groups are the tert-butoxycarbonyl (Boc) and the fluorenylmethoxycarbonyl (Fmoc) groups. More particular protecting group is the tert-butoxycarbonyl (Boc) group.
- uM means microMolar and is equivalent to the symbol M.
- the abbreviation uL means microliter and is equivalent to the symbol ⁇ L.
- the abbreviation ug means microgram and is equivalent to the symbol ⁇ g.
- the compounds of formula (I) can contain several asymmetric centers and can be present in the form of optically pure enantiomers, mixtures of enantiomers such as, for example, racemates, optically pure diastereoisomers, mixtures of diastereoisomers, diastereoisomeric racemates or mixtures of diastereoisomeric racemates.
- the asymmetric carbon atom can be of the “R” or “S” configuration.
- an embodiment of the present invention are compounds according to formula (I) as described herein and pharmaceutically acceptable salts or esters thereof, in particular compounds according to formula (I) as described herein and pharmaceutically acceptable salts thereof, more particularly compounds according to formula (I) as described herein.
- a more particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein the compounds are of formula (Ic).
- R 1 is substituted quinolinyl, substituted 1,2,3,4-tetrahydroquinolinyl, substituted isoquinolinyl, substituted 1,2,3,4-tetrahydroisoquinolinyl, substituted 9H-carbazolyl, substituted chromanyl, substituted indolyl, substituted naphthyl, substituted oxazolyl, substituted phenyl, substituted phenylalkyl, substituted phenoxyalkyl, substituted phenylalkoxy, substituted phenylalkenyl, substituted pyridazinyl, substituted pyridinyl, substituted pyridinonyl, substituted tetralinyl or substituted tetralinonyl, wherein substituted quinolinyl, substituted 1,2,3,4-tetrahydroquinolinyl, substituted isoquino
- a particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 1 is substituted quinolinyl, substituted indolyl, substituted naphthyl, substituted phenylalkoxy, substituted phenylalkenyl or substituted pyridinyl, wherein substituted quinolinyl, substituted indolyl, substituted naphthyl, substituted phenylalkoxy, substituted phenylalkenyl and substituted pyridinyl are substituted with R 6 , R 7 and R 8 .
- a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 2 is the ring system A and of formula (Ia).
- an embodiment of the present invention are compounds according to formula (I) as described herein, wherein Y is —C(O)—.
- Another embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 3 , R 4 and R 5 are independently selected from H and halogen.
- a further embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 3 , R 4 and R 5 are H.
- the present invention also relates to compounds according to formula (I) as described herein, wherein R 6 is H, halogen, cyano, cyanoalkyl, alkyl, haloalkyl, cycloalkylalkoxy, alkoxy, alkoxyalkyl, haloalkoxy, alkoxyalkoxy, phenyl, phenylalkoxy or phenyl substituted with one to three halogen.
- a further embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 6 is alkoxy, haloalkoxy or alkoxyalkoxy.
- R 7 is H, halogen, alkyl, cycloalkyl, alkoxy, haloalkoxy, alkylsulfonyl, furanyl or tetrahydropyranyl.
- a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 7 is H or halogen.
- a particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 8 is H.
- a more particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein R 1 is substituted quinolinyl, substituted indolyl, substituted naphthyl or substituted pyridinyl, wherein substituted quinolinyl, substituted indolyl, substituted naphthyl and substituted pyridinyl are substituted with R 6 , R 7 and R 8 , Y is —C(O)— and R 2 is the ring system A and of formula (Ib).
- a further particular embodiment of the present invention are compounds according to formula (I) as described herein, wherein the compounds are of formula (Ic).
- the preparation of compounds of formula (I) of the present invention may be carried out in sequential or convergent synthetic routes. Syntheses of the invention are shown in the following general schemes. The skills required for carrying out the reactions and purifications of the resulting products are known to those persons skilled in the art. In case a mixture of enantiomers or diastereoisomers is produced during a reaction, these enantiomers or diastereoisomers can be separated by methods described herein or known to the man skilled in the art such as e.g. (chiral) chromatography or crystallization. The substituents and indices used in the following description of the processes have the significance given herein.
- R 1 substituted phenylalkyl
- the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence or not of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof
- a base e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- phosgene or a phosgene equivalent e. g., diphosgene, triphosgene
- the imidazole-1-carboxylate esters 3A are typically not isolated but directly reacted with amines 1 as described above.
- the succinimidyl carbonate derivatives 3B are typically not isolated but directly reacted with amines 1 as described above.
- Alcohols of formula R 1 —OH are commercially available or can be produced by methods described herein or known in the art.
- amine 1 is reacted with a suitable N-(chlorocarbonyl)-1,2,3,4-tetrahydroisoquinoline 4, leading to compounds of formula (I) wherein R 1 is substituted 1,2,3,4-tetrahydroisoquinolin-2-yl.
- N-(chlorocarbonyl)-1,2,3,4-tetrahydroisoquinolines (4) are synthesised from the corresponding 1,2,3,4-tetrahydroisoquinolines 5 by reaction with phosgene or a phosgene equivalent, as described herein or in the literature.
- amine 1 is reacted with a suitable carboxylic acid of formula R 1 —COOH (6) leading to a compound of formula (I).
- the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, tetrahydrofuran, N,
- Amine 1 can also be reacted with suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula (I).
- suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula (I).
- the reaction is performed in a solvent such as dichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in the presence of a base such as triethylamine or 4-methylmorpholine, at temperatures between 0° C. and 80° C.
- Carboxylic acids (6) and acyl halides (7) are commercially available or can be prepared as described herein or in the literature.
- amine 1 is reacted with a suitable sulfonyl chloride of formula R 1 —SO 2 Cl (8), leading to compounds of formula (I) wherein Y is —S(O 2 )—.
- a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- Sulfonyl chlorides (8) are commercially available or can be synthesised as described herein or in the literature.
- Amines of general formula 1 are synthesised from tert-butyl carbamate precursors 9.
- the deprotection of 9 may be performed in the presence of a suitable acid, e. g, hydrochloric acid or trifluoroacetic acid, in a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane at temperatures between 0° C. and 30° C., leading to amine 1.
- a suitable acid e. g, hydrochloric acid or trifluoroacetic acid
- a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane
- Amides 9 can be produced from amine 10 by reaction with appropriate reagents, using methods known in the art.
- amine 10 is reacted with a suitable carboxylic acid of formula R 2 —COOH (11), leading to compounds of formula 9,
- a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, tetrahydrofuran, N,N-d
- Boc-protected amine 10 can be produced from diamine 12 using a suitable reagent, e. g., di-tert-butyl dicarbonate.
- a suitable reagent e. g., di-tert-butyl dicarbonate.
- the reaction is performed in a suitable solvent, e. g., dichloromethane, chloroform, or tetrahydrofuran, at temperatures between 0° C. and 30° C.
- 10 can be produced from 12 in a two step sequence.
- 12 is reacted with excess di-tert-butyl dicarbonate, leading to the diprotected intermediate 13.
- the dicarbamate 13 is mono-deprotected under suitable conditions, e. g., with hydrogen chloride, in solvents such as ethyl acetate, diethyl ether, 2-propanol, or mixtures thereof, leading to 10 as the hydrochloride salt.
- Amines of general formula 1 can also be synthesised from diamine 12 by reaction with appropriate reagents, using methods known in the art. For instance, diamine 12 is reacted with a suitable carboxylic acid of formula R 2 —COOH (11), leading to compounds of formula 1, The reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethyl aminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluoro
- amine 14 is reacted with a suitable carboxylic acid of formula R 2 —COOH (11), leading to compounds of formula (I).
- the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, tetrahydrofuran, N,N
- Amines 14 can be synthesised from diamine 12, using methods and reagents known in the art.
- R 1 substituted phenylalkyl
- the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence or not of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof
- a base e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- diamine 12 is reacted with a suitable N-(chlorocarbonyl)-1,2,3,4-tetrahydroisoquinoline 4, leading to compounds of formula 14 wherein R 1 is substituted 1,2,3,4-tetrahydroisoquinolin-2-yl.
- diamine 12 is reacted with a suitable carboxylic acid of formula R 1 —COOH (6) leading to a compound of formula 14.
- the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, tetrahydrofuran, N,N-
- Diamine 12 can also be reacted with suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula 14.
- suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula 14.
- the reaction is performed in a solvent such as dichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in the presence of a base such as triethylamine or 4-methylmorpholine, at temperatures between 0° C. and 80° C.
- diamine 12 is reacted with a suitable sulfonyl chloride of formula R 1 —SO 2 C (8), leading to compounds of formula 14 wherein Y is —S(O 2 )—.
- the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- a base e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- amines 14 can be synthesised from their tert-butyl carbamate derivatives of formula 15 by carbamate deprotection.
- the deprotection may be performed in the presence of a suitable acid, e. g, hydrochloric acid or trifluoroacetic acid, in a solvent such as water, 2-propanol, dichloromethane, or 1,4-dioxane, at temperatures between 0° C. and 30° C.
- Intermediates 15 can be produced from amine 10 by reaction with appropriate reagents, using methods known in the art.
- the reaction is performed in a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence or not of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof
- a base e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- amine 10 is reacted with a suitable N-(chlorocarbonyl)-1,2,3,4-tetrahydroisoquinoline 4, leading to compounds of formula 15 wherein R 1 is substituted 1,2,3,4-tetrahydroisoquinolin-2-yl.
- amine 10 is reacted with a suitable carboxylic acid of formula R 1 —COOH (6) leading to a compound of formula 15.
- the reaction is performed in the presence of a coupling agent such as 1,1′-carbonyldiimidazole, N,N′-dicyclohexylcarbodiimide, 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride, O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate, O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate or bromo-tris-pyrrolidino-phosphonium hexafluorophosphate, in aprotic solvents such as dichloromethane, tetrahydrofuran, N,N-
- Amine 12 can also be reacted with suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula 15.
- suitable acylating reagents such as acyl chlorides of formula R 1 —COCl (7) to lead to compounds of formula 15.
- the reaction is performed in a solvent such as dichloromethane, tetrahydrofuran, or N,N-dimethylformamide, in the presence of a base such as triethylamine or 4-methylmorpholine, at temperatures between 0° C. and 80° C.
- amine 10 is reacted with a suitable sulfonyl chloride of formula R 1 —SO 2 Cl (8), leading to compounds of formula 15 wherein Y is —S(O 2 )—.
- a suitable solvent such as dichloromethane, tetrahydrofuran, N,N-dimethylformamide, acetonitrile, acetone, water, or mixtures thereof, in the presence of a base, e. g., triethylamine, diisopropylethylamine, pyridine, potassium hydrogencarbonate, potassium carbonate, at temperatures between 0° C. and the boiling point of the solvent or solvent mixture.
- Diamine 12 can be synthesised in three step from N-benzylmaleimide (16), as illustrated in scheme 1.
- This reaction is performed in a suitable solvent, e. g., acetonitrile or dichloromethane, at temperatures between ⁇ 30° C. and +40° C.
- the reaction can be performed either in batch mode or, more preferably, in a continuous flow reactor.
- the dimeric products can be formed as a mixture of stereoisomers (i. e., 3aS,3bS,6aR,6bR-17 and 3aS,3bR,6aS,6bR-17), which can be separated, e. g., by crystallisation.
- step 2 diimide 17 is reduced to the corresponding diamine 18, using reagents and conditions known in the art.
- the reaction is performed, e. g., using lithium aluminum hydride, in a solvent such as diethyl ether or tetrahydrofuran, at temperatures between 0° C. and the boiling point of the solvent.
- step 3 scheme 1, the benzyl groups of 18 are removed, leading to diamine 12, using methods and reagents known in the art, e. g., by catalytic hydrogenation.
- the reaction is performed in a suitable solvent, e. g., methanol or ethanol, at hydrogen pressures between 1 bar and 100 bar, at temperatures between 0° C. and 100° C., in the presence of a suitable catalyst, e. g., palladium on activated charcoal.
- a suitable solvent e. g., methanol or ethanol
- an embodiment of the present invention is a process to prepare a compound of formula (I) as defined above comprising the reaction of a compound of formula (II) in the presence of a compound of formula (III);
- R 1 , R 2 , A and Y are as defined above.
- a coupling agent such as O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluoro-phosphate
- a solvent such as N,N-dimethylformamide
- a base such as 4-methylmorpholine and at a temperature comprised between ⁇ 78° C. and reflux, particularly between ⁇ 10° C. and room temperature.
- an object of the present invention is a compound according to formula (I) as described herein for use as a therapeutically active substance.
- an object of the present invention is a pharmaceutical composition
- a pharmaceutical composition comprising a compound according to formula (I) as described herein and a therapeutically inert carrier.
- a more particular object of the invention is the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of fibrotic diseases, cancer and ocular conditions.
- a furthermore particular object of the invention is the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of fibrotic diseases and ocular conditions.
- Renal conditions include, but are not limited to, acute kidney injury and chronic renal disease with and without proteinuria including end-stage renal disease (ESRD).
- ESRD end-stage renal disease
- this includes decreased creatinine clearance and decreased glomerular filtration rate, micro-albuminuria, albuminuria and proteinuria, glomerulosclerosis with expansion of reticulated mesangial matrix with or without significant hypercellularity (particularly diabetic nephropathy and amyloidosis), focal thrombosis of glomerular capillaries (particularly thrombotic microangiopathies), global fibrinoid necrosis, ischemic lesions, malignant nephrosclerosis (such as ischemic retraction, reduced renal blood flow and renal arteriopathy), swelling and proliferation of intracapillary (endothelial and mesangial) and/or extracapillary cells (crescents) like in glomerular nephritis entities, focal segmental glomerular sclerosis, IgA
- Liver conditions include, but are not limited to, liver cirrhosis, hepatic congestion, cholestatic liver disease including pruritus, nonalcoholic steatohepatitis and acute and chronic liver transplant rejection.
- Inflammatory conditions include, but are not limited to, arthritis, osteoarthritis, multiple sclerosis, systemic lupus erythematodes, inflammatory bowel disease, abnormal evacuation disorder and the like as well as inflammatory airways diseases such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) or chronic asthma bronchiale.
- IPF idiopathic pulmonary fibrosis
- COPD chronic obstructive pulmonary disease
- chronic asthma bronchiale chronic asthma bronchiale.
- Further conditions of the respiratory system include, but are not limited to, other diffuse parenchymal lung diseases of different etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, systemic diseases and vasculitides, granulomatous diseases (sarcoidosis, hypersensitivity pneumonia), collagen vascular disease, alveolar proteinosis, Langerhans cell granulomatosis, lymphangioleiomyomatosis, inherited diseases (Hermansky-Pudlak Syndrome, tuberous sclerosis, neurofibromatosis, metabolic storage disorders, familial interstitial lung disease), radiation induced fibrosis, silicosis, asbestos induced pulmonary fibrosis or acute respiratory distress syndrome (ARDS).
- iatrogenic drug-induced fibrosis etiologies including iatrogenic drug-induced fibrosis, occupational and/or environmental induced fibrosis, systemic diseases and vasculitides, granulomatous diseases (s
- Conditions of the nervous system include, but are not limited to, neuropathic pain, schizophrenia, neuro-inflammation (e.g. astrogliosis), peripheral and/or autonomic (diabetic) neuropathies and the like.
- Vascular conditions include, but are not limited to, atherosclerosis, thrombotic vascular disease as well as thrombotic microangiopathies, proliferative arteriopathy (such as swollen myointimal cells surrounded by mucinous extracellular matrix and nodular thickening), atherosclerosis, decreased vascular compliance (such as stiffness, reduced ventricular compliance and reduced vascular compliance), endothelial dysfunction and the like.
- Cardiovascular conditions include, but are not limited to, acute coronary syndrome, coronary heart disease, myocardial infarction, arterial and pulmonary hypertension, cardiac arrhythmia such as atrial fibrillation, stroke and other vascular damage.
- Fibrotic diseases include, but are not limited to myocardial and vascular fibrosis, renal fibrosis, liver fibrosis, pulmonary fibrosis, skin fibrosis, scleroderma and encapsulating peritonitis.
- a particular fibrotic disease is idiopathic pulmonary fibrosis.
- the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of organ or skin fibrosis.
- the fibrotic disease is renal tubulo-interstitial fibrosis or glomerulosclerosis.
- the fibrotic disease is non-alcoholic liver steatosis, liver fibrosis or liver cirrhosis.
- the fibrotic disease is idiopathic pulmonary fibrosis.
- Cancer and cancer metastasis include, but are not limited to, breast cancer, ovarian cancer, lung cancer, prostate cancer, mesothelioma, glioma, hepatic carcinoma, gastrointestinal cancers and progression and metastatic aggressiveness thereof.
- Ocular conditions include, but are not limited to, proliferative and non-proliferative (diabetic) retinopathy, dry and wet age-related macular degeneration (AMD), (diabetic) macular edema, central arterial/venous occlusion, traumatic injury, glaucoma and the like.
- a particular ocular condition is glaucoma.
- Metabolic conditions include, but are not limited to, obesity and diabetes.
- the compounds of formula (I) or their pharmaceutically acceptable salts and esters can be used for the treatment or prophylaxis of cholestatic or non-cholestatic chronic pruritus.
- the present invention also relates to the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
- the present invention also particularly relates to the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of fibrotic diseases, cancer and ocular conditions.
- the present invention also more particularly relates to the use of a compound according to formula (I) as described herein for the treatment or prophylaxis of fibrotic diseases and ocular conditions.
- Another embodiment of the present invention is a compound according to formula (I) as described herein for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
- Another particular embodiment of the present invention is a compound according to formula (I) as described herein for the treatment or prophylaxis fibrotic diseases, cancer and ocular conditions.
- Another more particular embodiment of the present invention is a compound according to formula (I) as described herein for the treatment or prophylaxis fibrotic diseases and ocular conditions.
- the present invention also relates to the use of a compound according to formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection.
- the present invention also particularly relates to the use of a compound according to formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of fibrotic diseases, cancer and ocular conditions.
- the present invention also further particularly relates to the use of a compound according to formula (I) as described herein for the preparation of a medicament for the treatment or prophylaxis of fibrotic diseases and ocular conditions.
- an object of the invention is a method for the treatment or prophylaxis of renal conditions, liver conditions, inflammatory conditions, conditions of the nervous system, conditions of the respiratory system, vascular and cardiovascular conditions, fibrotic diseases, cancer, ocular conditions, metabolic conditions, cholestatic and other forms of chronic pruritus and acute and chronic organ transplant rejection, which method comprises administering an effective amount of a compound according to formula (I) as described herein.
- a particular object of the invention is a method for the treatment or prophylaxis of fibrotic diseases, cancer and ocular conditions, which method comprises administering an effective amount of a compound according to formula (I) as described herein.
- a more particular object of the invention is a method for the treatment or prophylaxis of fibrotic diseases and ocular conditions, which method comprises administering an effective amount of a compound according to formula (I) as described herein.
- the renal condition is selected from the group consisting of acute kidney injury, chronic kidney disease, diabetic nephropathy, acute kidney transplant rejection and chronic allograft nephropathy.
- the renal condition is acute kidney injury.
- the renal condition is chronic kidney disease.
- the renal condition is diabetic nephropathy.
- the renal condition is acute kidney transplant rejection.
- the renal condition is chronic allograft nephropathy.
- the liver condition is acute and chronic liver transplant rejection
- the inflammatory condition is arthritis.
- the condition of the nervous system is neuropathic pain.
- the fibrotic disease is encapsulating peritonitis
- the fibrotic disease is idiopathic pulmonary fibrosis.
- the fibrotic disease is non-alcoholic liver steatosis, liver fibrosis or liver cirrhosis.
- cDNA was prepared from commercial human hematopoietic cells total RNA and used as template in overlapping PCR to generate a full length human ENPP2 ORF with or without a 3′-6 ⁇ His tag. These full length inserts were cloned into the pcDNA3.1V5-His TOPO (Invitrogen) vector. The DNA sequences of several single clones were verified. The DNA from a correct full length clone was used to transfect Hek293 cells for verification of protein expression. The sequence of the encoded ENPP2 conforms to Swissprot entry Q13822, with or without the additional C-terminal 6 ⁇ His tag.
- Recombinant protein was produced by large-scale transient transfection in 20 L controlled stirred tank bioreactors (Sartorius). During cell growth and transfection, temperature, stirrer speed, pH and dissolved oxygen concentration were maintained at 37° C., 120 rpm, 7.1 and 30% DO, respectively.
- FreeStyle 293-F cells (Invitrogen) were cultivated in suspension in FreeStyle 293 medium (Invitrogen) and transfected at ca. 1-1.5 ⁇ 10E6 cells/mL with above plasmid DNAs using X-tremeGENE Ro-1539 (commercial product, Roche Diagnostics) as complexing agent.
- the cleared supernatant was then applied to a HisTrap column (GE Healthcare) previously equilibrated in 50 mM Na 2 HPO 4 pH 7.0, 0.5 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 .
- the column was washed stepwise with the same buffer containing 20 mM, 40 mM and 50 mM imidazole, respectively.
- the protein was subsequently eluted using a linear gradient to 0.5 M imidazole in 15 column volumes.
- ATX containing fractions were pooled and concentrated using an Amicon cell equipped with a 30 kDa PES filter membrane.
- the protein was further purified by size exclusion chromatography on Superdex S-200 prep grade (XK 26/100) (GE Healthcare) in 20 mM BICINE pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 . Final yield of protein after purification was 5-10 mg ATX per liter of culture supernatant. The protein was stored at ⁇ 80° C.
- ATX inhibition was measured by a fluorescence quenching assay using a specifically labeled substrate analogue (MR121 substrate).
- MR121 substrate a specifically labeled substrate analogue
- BOC and TBS protected 6-amino-hexanoic acid (R)-3-( ⁇ 2-[3-(2- ⁇ 2-[2-(2-amino-ethoxy)-ethoxy]-ethoxy ⁇ -ethoxy)-propionylamino]-ethoxy ⁇ -hydroxy-phosphoryloxy)-2-hydroxy-propyl ester (Ferguson et al., Org Lett 2006, 8 (10), 2023) was labeled with MR121 fluorophore (CAS 185308-24-1, 1-(3-carboxypropyl)-11-ethyl-1,2,3,4,8,9,10,11-octahydro-dipyrido[3,2-b:2′,3′-i]phenoxazin-13-ium) on the free amine of the ethanolamine
- Assay working solutions were made as follows: Assay buffer (50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.01% Triton-X-100, pH 8.0; ATX solution: ATX (human His-tagged) stock solution (1.08 mg/mL in 20 mM bicine, pH 8.5, 0.15 M NaCl, 10% glycerol, 0.3% CHAPS, 0.02% NaN 3 ), diluted to 1.4-2.5 ⁇ final concentration in assay buffer; MR121 substrate solution: MR121 substrate stock solution (800 ⁇ M MR121 substrate in DMSO), diluted to 2-5 ⁇ final concentration in assay buffer.
- Assay buffer 50 mM Tris-HCl, 140 mM NaCl, 5 mM KCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 0.01% Triton-X-100, pH
- Test compounds (10 mM stock in DMSO, 8 ⁇ L) were obtained in 384 well sample plates (Corning Costar #3655) and diluted with 8 ⁇ L DMSO. Row-wise serial dilutions were made by transferring 8 ⁇ L cpd solution to the next row up to row O. The compound and control solutions were mixed five times and 2 ⁇ L were transferred to 384 well assay plates (Corning Costar #3702). Then, 15 ⁇ L of 41.7 nM ATX solution was added (30 nM final concentration), mixed five times and then incubated for 15 minutes at 30° C. 10 ⁇ L of MR121 substrate solution was added (1 ⁇ M final concentration), mixed 30 times and then incubated for 15 minutes at 30° C.
- Example IC50 ( ⁇ M) 1 0.034 1.001 0.011 1.002 0.064 1.003 0.0085 1.004 0.017 1.005 0.12 1.006 0.008 1.007 0.062 1.008 0.036 1.009 0.008 1.010 0.016 1.011 0.008 1.012 0.086 1.013 0.054 1.014 0.045 1.015 0.011 1.016 0.017 1.017 0.008 1.018 0.016 1.019 0.0115 1.020 0.006 1.021 0.265 1.022 0.155 1.023 1.473 1.024 0.377 1.025 0.0085 1.026 0.0115 1.027 0.828 1.028 2.834 1.029 0.07 1.030 0.104 1.031 0.224 1.032 0.013 1.033 0.104 1.034 0.489 1.035 0.243 1.036 0.13 1.037 0.1587 1.038 0.687 1.039 3.33 1.040 8.674 1.041 0.538 1.042 0.632
- the compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments (e.g. in the form of pharmaceutical preparations).
- the pharmaceutical preparations can be administered internally, such as orally (e.g. in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions or suspensions), nasally (e.g. in the form of nasal sprays) or rectally (e.g. in the form of suppositories).
- the administration can also be effected parenterally, such as intramuscularly or intravenously (e.g. in the form of injection solutions).
- the compounds of formula (I) and their pharmaceutically acceptable salts can be processed with pharmaceutically inert, inorganic or organic adjuvants for the production of tablets, coated tablets, dragées and hard gelatin capsules.
- Lactose, corn starch or derivatives thereof, talc, stearic acid or its salts etc. can be used, for example, as such adjuvants for tablets, dragées and hard gelatin capsules.
- Suitable adjuvants for soft gelatin capsules are, for example, vegetable oils, waxes, fats, semi-solid substances and liquid polyols, etc.
- Suitable adjuvants for the production of solutions and syrups are, for example, water, polyols, saccharose, invert sugar, glucose, etc.
- Suitable adjuvants for injection solutions are, for example, water, alcohols, polyols, glycerol, vegetable oils, etc.
- Suitable adjuvants for suppositories are, for example, natural or hardened oils, waxes, fats, semi-solid or liquid polyols, etc.
- the pharmaceutical preparations can contain preservatives, solubilizers, viscosity-increasing substances, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorants, salts for varying the osmotic pressure, buffers, masking agents or antioxidants. They can also contain still other therapeutically valuable substances.
- the dosage can vary in wide limits and will, of course, be fitted to the individual requirements in each particular case.
- the pure enantiomers can be obtained by methods described herein or by methods known to those skilled in the art, such as e.g. chiral chromatography or crystallization.
- Step 1 (3aS,3bS,6aR,6bR)-2,5-Dibenzyl-tetrahydro-cyclobuta[1,2-c;3,4-c′]dipyrrole-1,3,4,6-tetraone
- Step 2 (3aS,3bS,6aR,6bR)-2,5-Dibenzyl-decahydro-cyclobuta[1,2-c;3,4-c′]dipyrrole
- Step 3 (3aS,3bS,6aR,6bR)-Decahydro-cyclobuta[1,2-c;3,4-c′]dipyrrole
- Lithium hydroxide monohydrate (102 mg, 2.4 mmol) was added to a solution of methyl 5-chloro-6-oxo-1-(2,2,2-trifluoroethyl)-1,6-dihydropyridine-3-carboxylate (328 mg, 1.22 mmol) in tetrahydrofuran (1 mL) and water (1 mL), then after 16 h the reaction mixture was partially evaporated in order to remove most of the tetrahydrofuran. The remaining aqueous solution was acidified to pH 1 with 1 M aq. hydrochloric acid solution. The precipitate was collected by filtration and dried to afford the title compound (289 mg, 93%). White solid, MS: 254.2 (M ⁇ H) ⁇ .
- Racemic 4,5,6,7-tetrahydro-1H-benzo[d][1,2,3]triazole-5-carboxylic acid (CAS-RN 33062-47-4; 1.10 g, 6.58 mmol) was separated by preparative HPLC using a Chiralpak AD column as the stationary phase and heptane/ethanol 3:2 as the mobile phase. This produced the faster eluting (+)-(R)-enantiomer (452 mg, 41%), followed by the slower eluting ( ⁇ )-(S)-enantiomer (381 mg, 35%).
- Step 1 (3aS,3bS,6aR,6bR)-Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrole-2,5-dicarboxylic acid di-tert-butyl ester
- Step 2 (3aR,3bS,6aR,6bS)-Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrole-2-carboxylic acid tert-butyl ester hydrochloride
- a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of tablets of the following composition:
- a compound of formula (I) can be used in a manner known per se as the active ingredient for the production of capsules of the following composition:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/997,341 US10849881B2 (en) | 2013-11-26 | 2018-06-04 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
US17/034,323 US20210015792A1 (en) | 2013-11-26 | 2020-09-28 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13194475.3 | 2013-11-26 | ||
EP13194475 | 2013-11-26 | ||
PCT/EP2014/075360 WO2015078803A1 (en) | 2013-11-26 | 2014-11-24 | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2014/075360 Continuation WO2015078803A1 (en) | 2013-11-26 | 2014-11-24 | NEW OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/997,341 Continuation US10849881B2 (en) | 2013-11-26 | 2018-06-04 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
Publications (1)
Publication Number | Publication Date |
---|---|
US20160264586A1 true US20160264586A1 (en) | 2016-09-15 |
Family
ID=49726473
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/164,122 Abandoned US20160264586A1 (en) | 2013-11-26 | 2016-05-25 | OCTAHYDRO-CYCLOBUTA [1,2-c;3,4-c']DIPYRROL-2-YL |
US15/997,341 Active US10849881B2 (en) | 2013-11-26 | 2018-06-04 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
US17/034,323 Abandoned US20210015792A1 (en) | 2013-11-26 | 2020-09-28 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/997,341 Active US10849881B2 (en) | 2013-11-26 | 2018-06-04 | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
US17/034,323 Abandoned US20210015792A1 (en) | 2013-11-26 | 2020-09-28 | OCTAHYDRO-CYCLOBUTA[1,2-c;3,4-c']DIPYRROL-2-YL |
Country Status (32)
Country | Link |
---|---|
US (3) | US20160264586A1 (lt) |
EP (1) | EP3074400B1 (lt) |
JP (1) | JP6496730B2 (lt) |
KR (1) | KR20160087900A (lt) |
CN (1) | CN105764905B (lt) |
AR (1) | AR098517A1 (lt) |
AU (1) | AU2014356583B2 (lt) |
CA (1) | CA2923523A1 (lt) |
CL (1) | CL2016001266A1 (lt) |
CR (1) | CR20160171A (lt) |
DK (1) | DK3074400T3 (lt) |
EA (1) | EA201691044A1 (lt) |
ES (1) | ES2656198T3 (lt) |
HK (1) | HK1223921A1 (lt) |
HR (1) | HRP20180029T1 (lt) |
HU (1) | HUE036117T2 (lt) |
IL (1) | IL244519A0 (lt) |
LT (1) | LT3074400T (lt) |
MA (1) | MA38982A1 (lt) |
MX (1) | MX2016005186A (lt) |
MY (1) | MY187449A (lt) |
NO (1) | NO3074400T3 (lt) |
PE (1) | PE20160845A1 (lt) |
PH (1) | PH12016500643B1 (lt) |
PL (1) | PL3074400T3 (lt) |
PT (1) | PT3074400T (lt) |
RS (1) | RS56776B1 (lt) |
SI (1) | SI3074400T1 (lt) |
TW (1) | TW201605861A (lt) |
UA (1) | UA118201C2 (lt) |
WO (1) | WO2015078803A1 (lt) |
ZA (1) | ZA201601726B (lt) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9802944B2 (en) | 2014-03-26 | 2017-10-31 | Hoffmann-La Roche Inc. | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US10633384B2 (en) | 2012-06-13 | 2020-04-28 | Hoffmann-La Roche Inc. | Diazaspirocycloalkane and azaspirocycloalkane |
US10640472B2 (en) | 2015-09-04 | 2020-05-05 | Hoffman-La Roche Inc. | Phenoxymethyl derivatives |
US10647719B2 (en) | 2015-09-24 | 2020-05-12 | Hoffmann-La Roche Inc. | Bicyclic compounds as dual ATX/CA inhibitors |
US10669285B2 (en) | 2014-03-26 | 2020-06-02 | Hoffmann-La Roche Inc. | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US10669268B2 (en) | 2012-09-25 | 2020-06-02 | Hoffmann-La Roche Inc. | Bicyclic derivatives |
US10676446B2 (en) | 2015-04-10 | 2020-06-09 | Hoffmann-La Roche Inc. | Bicyclic quinazolinone derivatives |
US10738053B2 (en) | 2015-09-24 | 2020-08-11 | Hoffmann-La Roche Inc. | Bicyclic compounds as dual ATX/CA inhibitors |
US10787459B2 (en) | 2015-09-24 | 2020-09-29 | Hoffmann-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US10800786B2 (en) | 2015-09-24 | 2020-10-13 | Hoffman-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US10849881B2 (en) | 2013-11-26 | 2020-12-01 | Hoffmann-La Roche Inc. | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
US10882857B2 (en) | 2017-03-16 | 2021-01-05 | Hoffmann-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US10913745B2 (en) | 2013-03-12 | 2021-02-09 | Hoffmann-La Roche Inc. | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors |
US11059794B2 (en) | 2017-03-16 | 2021-07-13 | Hoffmann-La Roche Inc. | Heterocyclic compounds useful as dual ATX/CA inhibitors |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108456208B (zh) * | 2017-02-22 | 2021-04-16 | 广州市恒诺康医药科技有限公司 | 氮杂螺环类化合物及其制备方法和应用 |
FR3079742B1 (fr) | 2018-04-06 | 2023-01-13 | Keranova | Appareil de traitement d’un tissu incluant des systemes optiques originaux de deviation et de focalisation d’un faisceau l.a.s.e.r. |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017050792A1 (en) * | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
Family Cites Families (137)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1252898B (de) | 1965-06-12 | 1967-10-26 | Bayer Ag | Verfahren zur Herstellung von Copolymerisaten des Trioxans |
US5240928A (en) | 1989-07-03 | 1993-08-31 | Merck & Co., Inc. | Substituted quinazolinones as angiotensin II antagonists |
DE3930262A1 (de) | 1989-09-11 | 1991-03-21 | Thomae Gmbh Dr K | Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
KR910009330B1 (ko) | 1989-10-23 | 1991-11-11 | 재단법인 한국화학연구소 | 항균작용을 갖는 퀴놀린계 화합물과 그의 제조방법 |
CA2037630C (en) | 1990-03-07 | 2001-07-03 | Akira Morimoto | Nitrogen-containing heterocylic compounds, their production and use |
US5470975A (en) | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
US5290780A (en) | 1991-01-30 | 1994-03-01 | American Cyanamid Co. | Angiotensin II receptor blocking 2,3,6 substituted quinazolinones |
US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
DE4121214A1 (de) | 1991-06-27 | 1993-01-14 | Bayer Ag | 7-azaisoindolinyl-chinolon- und -naphthyridoncarbonsaeure-derivate |
US5202322A (en) | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
US5532243A (en) | 1992-02-14 | 1996-07-02 | The Dupont Merck Pharmaceutical Company | Antipsychotic nitrogen-containing bicyclic compounds |
US5358951A (en) | 1993-04-23 | 1994-10-25 | American Cyanamid Company | Angiotensin II receptor blocking 2, 3, 6 substituted quinazolinones |
DE4407047A1 (de) | 1994-03-03 | 1995-09-07 | Merck Patent Gmbh | Acetamide |
US20010016657A1 (en) | 1997-03-18 | 2001-08-23 | Smithkline Beecham P.L.C. | Substituted isoquinoline derivatives and their use as anticonvulsants |
EE200000458A (et) | 1998-02-04 | 2002-02-15 | Banyu Pharmaceutical Co., Ltd. | Tsüklilise amiini N-atsüülderivaadid |
JP2001039950A (ja) | 1999-07-30 | 2001-02-13 | Banyu Pharmaceut Co Ltd | N−アシル環状アミン誘導体 |
CA2389034A1 (en) | 1999-10-27 | 2001-05-03 | Cor Therapeutics, Inc. | Pyridyl-containing spirocyclic compounds as inhibitors of fibrinogen-dependent platelet aggregation |
WO2002070523A1 (en) | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulators of chemokine receptor activity |
EP1499306A4 (en) | 2002-04-12 | 2007-03-28 | Merck & Co Inc | BICYCLIC AMIDE |
GB0303852D0 (en) | 2003-02-19 | 2003-03-26 | Pfizer Ltd | Triazole compounds useful in therapy |
WO2005023762A1 (en) | 2003-09-04 | 2005-03-17 | Abbott Laboratories | Pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-iv (dpp-iv) |
SE0302811D0 (sv) | 2003-10-23 | 2003-10-23 | Astrazeneca Ab | Novel compounds |
GB0324790D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Amide derivatives |
US7226951B2 (en) | 2003-12-17 | 2007-06-05 | Allergan, Inc. | Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same |
KR100610731B1 (ko) | 2004-02-24 | 2006-08-09 | 한국과학기술연구원 | T-형 칼슘 채널 차단제로서 유용한 3,4-디히드로퀴나졸린유도체 및 그의 제조 방법 |
AU2005219438B2 (en) | 2004-03-03 | 2011-02-17 | Chemocentryx, Inc. | Bicyclic and bridged nitrogen heterocycles |
CA2569910A1 (en) | 2004-06-09 | 2005-12-22 | Eun Kyung Lee | Octahydro-pyrrolo[3,4-c] derivatives and their use as antiviral compounds |
CN101035773B (zh) | 2004-08-10 | 2012-06-06 | 詹森药业有限公司 | 抑制hiv的1,2,4-三嗪-6-酮衍生物 |
US7410949B2 (en) | 2005-01-18 | 2008-08-12 | Hoffmann-La Roche Inc. | Neuropeptide-2 receptor (Y-2R) agonists and uses thereof |
GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
BRPI0610433A2 (pt) | 2005-04-28 | 2010-11-23 | Wyeth Corp | forma polimórfica ii de tanaproget, processos para preparar a mesma, e para preparar forma micronizada de um composto, composição farmacêutica, método de preparação de uma composição farmacêutica, e, uso da forma polimórfica ii de tanaproget ou da forma micronizada |
US7737279B2 (en) | 2005-05-10 | 2010-06-15 | Bristol-Myers Squibb Company | 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same |
TW200800999A (en) | 2005-09-06 | 2008-01-01 | Astrazeneca Ab | Novel compounds |
DK1942108T3 (da) | 2005-10-28 | 2013-12-09 | Ono Pharmaceutical Co | Forbindelse indeholdende basisk gruppe samt anvendelse deraf |
PL1961744T3 (pl) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
JP2007176809A (ja) | 2005-12-27 | 2007-07-12 | Hideaki Natsukari | 複素環置換アミド化合物、その製造法および医薬組成物 |
WO2007103719A2 (en) | 2006-03-03 | 2007-09-13 | Incyte Corporation | MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME |
JP2008031064A (ja) | 2006-07-27 | 2008-02-14 | Astellas Pharma Inc | ジアシルピペラジン誘導体 |
EP2069315B1 (en) | 2006-09-11 | 2011-09-07 | N.V. Organon | Quinazolinone and isoquinolinone acetamide derivatives |
US7638526B2 (en) | 2006-09-15 | 2009-12-29 | Schering Corporation | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism |
US8735411B2 (en) | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
TWI405763B (zh) | 2006-11-02 | 2013-08-21 | Targacept Inc | 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺 |
WO2008059026A1 (en) | 2006-11-15 | 2008-05-22 | High Point Pharmaceuticals, Llc | Novel 2-(2-hydroxyphenyl)benzimidazoles useful for treating obesity and diabetes |
TW200831085A (en) | 2006-12-13 | 2008-08-01 | Merck & Co Inc | Non-nucleoside reverse transcriptase inhibitors |
EP1975165A1 (de) | 2007-03-27 | 2008-10-01 | Boehringer Ingelheim Pharma GmbH & Co. KG | Substituierte Pyrrolidinamide, deren Herstellung und deren Verwendung als Arzneimittel |
BRPI0809617A2 (pt) | 2007-03-29 | 2014-09-16 | Hoffmann La Roche | Inibidores não-nucleosídicos da transcriptase reversa |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
JP2010524987A (ja) | 2007-04-27 | 2010-07-22 | サノフィ−アベンティス | 2−ヘテロアリール−ピロロ[3,4−c]ピロール誘導体及びscd阻害剤としてのそれらの使用 |
UA99626C2 (ru) | 2007-08-07 | 2012-09-10 | Эбботт Гмбх Унд Ко. Кг | Соединения хинолина, пригодные для лечения нарушений, реагирующих на модуляцию рецептора 5-нт6 серотонина |
DE102007047737A1 (de) | 2007-10-05 | 2009-04-30 | Merck Patent Gmbh | Piperidin- und Piperazinderivate |
EP3797775A1 (en) | 2007-10-19 | 2021-03-31 | Novartis AG | Compositions and methods for treatment of diabetic retinopathy |
AR069126A1 (es) | 2007-10-31 | 2009-12-30 | Janssen Pharmaceutica Nv | Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa |
JP2009161449A (ja) | 2007-12-28 | 2009-07-23 | Lion Corp | Ppar活性促進剤並びに美容用飲食品、皮膚外用剤及び医薬 |
AU2009261248A1 (en) | 2008-06-19 | 2009-12-23 | Banyu Pharmaceutical Co., Ltd. | Spirodiamine-diarylketoxime derivative |
US8673917B2 (en) | 2008-09-09 | 2014-03-18 | Sanofi | 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors |
TW201020247A (en) | 2008-11-06 | 2010-06-01 | Gruenenthal Gmbh | Substituierte disulfonamide |
EP2358677B1 (en) | 2008-11-17 | 2014-01-08 | F. Hoffmann-La Roche AG | Naphthylacetic acids used as crth2 antagonists or partial agonists |
DE102008059578A1 (de) | 2008-11-28 | 2010-06-10 | Merck Patent Gmbh | Benzo-Naphtyridin Verbindungen |
BRPI0922154A2 (pt) | 2008-12-01 | 2016-01-05 | Merck Patent Gmbh | pirido[4,3-d]pirimidinas 2,5-diamino-substituídas como inibidores de autotaxina contra o cãncer |
TW201035102A (en) | 2009-03-04 | 2010-10-01 | Gruenethal Gmbh | Sulfonylated tetrahydroazolopyrazines and their use as medicinal products |
AU2010219705A1 (en) | 2009-03-05 | 2011-07-21 | Daiichi Sankyo Company, Limited | Pyridine derivative |
WO2010108268A1 (en) | 2009-03-23 | 2010-09-30 | Merck Frosst Canada Ltd. | Heterocyclic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
TW201038572A (en) | 2009-03-25 | 2010-11-01 | Gruenenthal Gmbh | Substituted spiro-amide compounds |
JP5779172B2 (ja) * | 2009-04-02 | 2015-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | オートタキシン阻害剤 |
EP2623101B1 (en) | 2009-04-02 | 2021-04-21 | Merck Patent GmbH | Piperidine and piperazine derivatives as autotaxin inhibitors |
KR20120027192A (ko) | 2009-04-02 | 2012-03-21 | 메르크 파텐트 게엠베하 | 오토탁신 저해제로서의 헤테로시클릭 화합물 |
FR2945534B1 (fr) | 2009-05-12 | 2012-11-16 | Sanofi Aventis | DERIVES DE CYCLOPENTAL[c]PYRROLE-2-CARBOXYLATES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE |
MX2011012345A (es) | 2009-05-22 | 2012-01-31 | Exelixis Inc | Inhibidores de pi3k/mtor basados en benzoxazepinas contra enfermedades proliferativas. |
WO2010141817A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
DE102009033392A1 (de) | 2009-07-16 | 2011-01-20 | Merck Patent Gmbh | Heterocyclische Verbindungen als Autotaxin-Inhibitoren II |
JP2013501064A (ja) | 2009-08-04 | 2013-01-10 | アミラ ファーマシューティカルス,インコーポレーテッド | リゾホスファチジン酸受容体アンタゴニストとしての化合物 |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
US8835427B2 (en) | 2010-01-07 | 2014-09-16 | E I Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
WO2011115813A1 (en) | 2010-03-18 | 2011-09-22 | Abbott Laboratories | Lactam acetamides as calcium channel blockers |
RU2524341C2 (ru) | 2010-03-19 | 2014-07-27 | Пфайзер Инк. | Производные 2,3-дигидро-1н-инден-1-ил-2,7-диазаспиро[3.5]нонана и их применение в качестве антагонистов или обратных агонистов грелинового рецептора |
CN102822171B (zh) | 2010-03-26 | 2015-09-02 | 默克专利有限公司 | 作为自分泌运动因子抑制剂的苯并萘啶胺类 |
GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
WO2011151461A2 (en) | 2010-06-04 | 2011-12-08 | B.S.R.C. "Alexander Fleming" | Autotaxin pathway modulation and uses thereof |
JP5781071B2 (ja) | 2010-06-29 | 2015-09-16 | オリンパス株式会社 | 光学素子の製造方法および光学素子の製造装置 |
JP2013536200A (ja) | 2010-08-20 | 2013-09-19 | アミラ ファーマシューティカルス,インコーポレーテッド | オートタキシン阻害剤およびその使用 |
EP2611808B1 (en) | 2010-09-02 | 2014-11-12 | Merck Patent GmbH | Pyrazolopyridinone derivatives as lpa receptor antagonists |
US8999985B2 (en) | 2010-12-02 | 2015-04-07 | Shanghai De Novo Pharmatech Co Ltd. | Substituted phthalazin-1(2H)-ones, preparation processes and medical uses thereof |
CN104906103B (zh) | 2010-12-14 | 2018-05-18 | 电泳有限公司 | 酪蛋白激酶1δ(CK1δ)抑制剂 |
EP2714680B1 (en) | 2011-05-27 | 2015-11-25 | Amira Pharmaceuticals, Inc. | Heterocyclic autotaxin inhibitors and uses thereof |
WO2013033059A1 (en) | 2011-08-29 | 2013-03-07 | Bristol-Myers Squibb Company | Spiro bicyclic diamine derivatives as hiv attachment inhibitors |
WO2013054185A1 (en) * | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
WO2013065712A1 (ja) | 2011-10-31 | 2013-05-10 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
US8809552B2 (en) | 2011-11-01 | 2014-08-19 | Hoffmann-La Roche Inc. | Azetidine compounds, compositions and methods of use |
JP5918859B2 (ja) | 2011-12-02 | 2016-05-18 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RARに関連するオーファン受容体−ガンマ(RORγ、NR1F3)活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド |
TWI638802B (zh) | 2012-05-24 | 2018-10-21 | 芬蘭商奧利安公司 | 兒茶酚o-甲基轉移酶活性抑制化合物 |
AR091424A1 (es) | 2012-06-13 | 2015-02-04 | Incyte Corp | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) |
PT2861566T (pt) | 2012-06-13 | 2017-02-08 | Hoffmann La Roche | Novos diazaspirocicloalcanos e azaspirocicloalcanos |
KR20150028999A (ko) | 2012-06-27 | 2015-03-17 | 에프. 호프만-라 로슈 아게 | 5-아자인다졸 화합물 및 이의 사용 방법 |
EA027809B1 (ru) | 2012-07-27 | 2017-09-29 | Биоген Айдек Ма Инк. | Соединения, которые являются s1p-модулирующими агентами и/или atx-модулирующими агентами |
JP6391571B2 (ja) | 2012-07-27 | 2018-09-19 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | Atx調節剤 |
AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
WO2014048881A1 (en) | 2012-09-25 | 2014-04-03 | Bayer Pharma Aktiengesellschaft | Combination of regorafenib and acetylsalicylic acid for treating cancer |
UA116547C2 (uk) | 2012-09-25 | 2018-04-10 | Ф. Хоффманн-Ля Рош Аг | Біциклічні похідні |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
CA2886263C (en) | 2012-10-25 | 2021-04-13 | Tetra Discovery Partners, LLC | Heteroaryl inhibitors of pde4 |
HUE030613T2 (en) | 2012-12-31 | 2017-05-29 | Cadila Healthcare Ltd | Substituted phthalazin-1 (2H) -one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 |
WO2014133112A1 (ja) | 2013-03-01 | 2014-09-04 | 国立大学法人東京大学 | オートタキシン阻害活性を有する8-置換イミダゾピリミジノン誘導体 |
TWI593692B (zh) | 2013-03-12 | 2017-08-01 | 美國禮來大藥廠 | 四氫吡咯并噻嗪化合物 |
KR20150126043A (ko) | 2013-03-12 | 2015-11-10 | 어큐셀라 인코포레이티드 | 안과 질환 및 장애 치료용 치환된 3-페닐프로필아민 유도체 |
AU2014231563A1 (en) | 2013-03-12 | 2015-09-17 | Abbvie Inc. | Tetracyclic bromodomain inhibitors |
AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
US20160039825A1 (en) | 2013-03-15 | 2016-02-11 | Biogen Ma Inc. | S1p and/or atx modulating agents |
TN2016000022A1 (en) | 2013-07-18 | 2017-07-05 | Novartis Ag | Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core |
WO2015058031A1 (en) | 2013-10-17 | 2015-04-23 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
BR112016010220B1 (pt) | 2013-11-22 | 2023-05-09 | Sabre Therapeutics Llc | Compostos inibidores de autoxatina, composições e usos relacionados |
AR098475A1 (es) | 2013-11-26 | 2016-06-01 | Bayer Cropscience Ag | Compuestos pesticidas y usos |
DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
UA119347C2 (uk) | 2014-03-26 | 2019-06-10 | Ф. Хоффманн-Ля Рош Аг | Конденсовані [1,4]діазепінові сполуки як інгібітори продукції аутотаксину (atх) та лізофосфатидилової кислоти (lpa) |
JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
JP2017515794A (ja) | 2014-03-26 | 2017-06-15 | ビーエーエスエフ ソシエタス・ヨーロピアBasf Se | 殺菌剤としての置換[1,2,4]トリアゾール及びイミダゾール化合物 |
MA50635A (fr) | 2014-03-26 | 2020-08-12 | Hoffmann La Roche | Nouveaux composés bicycliques comme inhibiteurs de la production d'autotaxin (atx) et de l'acide lysophosphatidique |
WO2015154023A1 (en) | 2014-04-04 | 2015-10-08 | X-Rx Discovery, Inc. | Substituted spirocydic inhibitors of autotaxin |
EP3187492A4 (en) | 2014-08-29 | 2018-05-09 | The University of Tokyo | Pyrimidinone derivative having autotaxin-inhibitory activity |
SI3207043T1 (sl) | 2014-10-14 | 2019-04-30 | Vitae Pharmaceuticals, Inc. | Dihidropirolopiridinovi inhibitorji za ROR-gama |
EA033497B1 (ru) | 2015-02-15 | 2019-10-31 | Hoffmann La Roche | 1-(тиофенил или фенил)сульфонил-(пирролидин)-2-карбоксамидные производные и их применение в качестве антагонистов trpa1 |
MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
CN104927727B (zh) | 2015-07-06 | 2017-01-11 | 香山红叶建设有限公司 | 一种玻璃幕墙用结构密封胶及其制备方法 |
PL415078A1 (pl) | 2015-09-04 | 2017-03-13 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Podstawione aminotriazole przydatne jako inhibitory kwaśnej chitynazy ssaków |
KR20180043837A (ko) | 2015-09-04 | 2018-04-30 | 에프. 호프만-라 로슈 아게 | 페녹시메틸 유도체 |
AR106135A1 (es) | 2015-09-24 | 2017-12-13 | Ionis Pharmaceuticals Inc | Moduladores de la expresión del sarcoma de la rata de kirsten (kras) |
CA2983782A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
WO2017050791A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
CA2984585A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual atx/ca inhibitors |
US10323038B2 (en) | 2015-11-20 | 2019-06-18 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
WO2017087858A1 (en) | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Pyrazole compounds and methods of making and using same |
BR112018009798A8 (pt) | 2015-11-25 | 2019-02-26 | Dana Farber Cancer Inst Inc | inibidores de bromodomínio bivalentes e usos dos mesmos |
AU2016362040B2 (en) | 2015-12-01 | 2019-10-10 | Nihon Nohyaku Co., Ltd. | 3H-pyrrolopyridine compound, N-oxide thereof or salt thereof, agricultural and horticultural insecticide comprising the compound and method for using the same |
WO2017139978A1 (zh) | 2016-02-19 | 2017-08-24 | 吴伟东 | 手机app更新方法及系统 |
CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ.ホフマン-ラ ロシュ アーゲー | Atxインヒビターとしての新規二環式化合物 |
NZ748072A (en) | 2017-03-20 | 2020-06-26 | Forma Therapeutics Inc | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
-
2014
- 2014-11-24 DK DK14805527.0T patent/DK3074400T3/en active
- 2014-11-24 EP EP14805527.0A patent/EP3074400B1/en active Active
- 2014-11-24 WO PCT/EP2014/075360 patent/WO2015078803A1/en active Application Filing
- 2014-11-24 MA MA38982A patent/MA38982A1/fr unknown
- 2014-11-24 PL PL14805527T patent/PL3074400T3/pl unknown
- 2014-11-24 CN CN201480064141.8A patent/CN105764905B/zh active Active
- 2014-11-24 ES ES14805527.0T patent/ES2656198T3/es active Active
- 2014-11-24 KR KR1020167016752A patent/KR20160087900A/ko not_active Application Discontinuation
- 2014-11-24 SI SI201430553T patent/SI3074400T1/en unknown
- 2014-11-24 AU AU2014356583A patent/AU2014356583B2/en not_active Ceased
- 2014-11-24 NO NO14805527A patent/NO3074400T3/no unknown
- 2014-11-24 HU HUE14805527A patent/HUE036117T2/hu unknown
- 2014-11-24 UA UAA201606880A patent/UA118201C2/uk unknown
- 2014-11-24 MX MX2016005186A patent/MX2016005186A/es unknown
- 2014-11-24 CA CA2923523A patent/CA2923523A1/en not_active Abandoned
- 2014-11-24 PT PT148055270T patent/PT3074400T/pt unknown
- 2014-11-24 PE PE2016000678A patent/PE20160845A1/es unknown
- 2014-11-24 MY MYPI2016701851A patent/MY187449A/en unknown
- 2014-11-24 EA EA201691044A patent/EA201691044A1/ru unknown
- 2014-11-24 LT LTEP14805527.0T patent/LT3074400T/lt unknown
- 2014-11-24 JP JP2016534720A patent/JP6496730B2/ja not_active Expired - Fee Related
- 2014-11-24 RS RS20180041A patent/RS56776B1/sr unknown
- 2014-11-25 AR ARP140104399A patent/AR098517A1/es unknown
- 2014-11-25 TW TW103140878A patent/TW201605861A/zh unknown
-
2016
- 2016-03-09 IL IL244519A patent/IL244519A0/en unknown
- 2016-03-14 ZA ZA2016/01726A patent/ZA201601726B/en unknown
- 2016-04-07 PH PH12016500643A patent/PH12016500643B1/en unknown
- 2016-04-14 CR CR20160171A patent/CR20160171A/es unknown
- 2016-05-25 CL CL2016001266A patent/CL2016001266A1/es unknown
- 2016-05-25 US US15/164,122 patent/US20160264586A1/en not_active Abandoned
- 2016-10-19 HK HK16112055.9A patent/HK1223921A1/zh unknown
-
2018
- 2018-01-08 HR HRP20180029TT patent/HRP20180029T1/hr unknown
- 2018-06-04 US US15/997,341 patent/US10849881B2/en active Active
-
2020
- 2020-09-28 US US17/034,323 patent/US20210015792A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017050792A1 (en) * | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
Non-Patent Citations (3)
Title |
---|
Benesh et al, FEBS Letters (2014), Vol 588, pp.2712-2727. * |
Gierse et al, J. Pharmacology and Exp. Therapeutics (2010), Vol 334, pp.310-317. * |
Jones et al, ACS Medicinal Chemistry Letters (2016), Vol 7, pp.857-861. * |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10633384B2 (en) | 2012-06-13 | 2020-04-28 | Hoffmann-La Roche Inc. | Diazaspirocycloalkane and azaspirocycloalkane |
US10669268B2 (en) | 2012-09-25 | 2020-06-02 | Hoffmann-La Roche Inc. | Bicyclic derivatives |
US10913745B2 (en) | 2013-03-12 | 2021-02-09 | Hoffmann-La Roche Inc. | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors |
US10849881B2 (en) | 2013-11-26 | 2020-12-01 | Hoffmann-La Roche Inc. | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl |
US10654857B2 (en) | 2014-03-26 | 2020-05-19 | Hoffman-La Roche Inc. | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US10669285B2 (en) | 2014-03-26 | 2020-06-02 | Hoffmann-La Roche Inc. | Condensed [1,4] diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US9802944B2 (en) | 2014-03-26 | 2017-10-31 | Hoffmann-La Roche Inc. | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US11098048B2 (en) | 2014-03-26 | 2021-08-24 | Hoffmann-La Roche Inc. | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
US10676446B2 (en) | 2015-04-10 | 2020-06-09 | Hoffmann-La Roche Inc. | Bicyclic quinazolinone derivatives |
US10640472B2 (en) | 2015-09-04 | 2020-05-05 | Hoffman-La Roche Inc. | Phenoxymethyl derivatives |
US11352330B2 (en) | 2015-09-04 | 2022-06-07 | Hoffmann-La Roche Inc. | Phenoxymethyl derivatives |
US10738053B2 (en) | 2015-09-24 | 2020-08-11 | Hoffmann-La Roche Inc. | Bicyclic compounds as dual ATX/CA inhibitors |
US10889588B2 (en) | 2015-09-24 | 2021-01-12 | Hoffmann-La Roche Inc. | Bicyclic compounds as dual ATX/CA inhibitors |
US10800786B2 (en) | 2015-09-24 | 2020-10-13 | Hoffman-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US10787459B2 (en) | 2015-09-24 | 2020-09-29 | Hoffmann-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US10647719B2 (en) | 2015-09-24 | 2020-05-12 | Hoffmann-La Roche Inc. | Bicyclic compounds as dual ATX/CA inhibitors |
US10882857B2 (en) | 2017-03-16 | 2021-01-05 | Hoffmann-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
US11059794B2 (en) | 2017-03-16 | 2021-07-13 | Hoffmann-La Roche Inc. | Heterocyclic compounds useful as dual ATX/CA inhibitors |
US11673888B2 (en) | 2017-03-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bicyclic compounds as ATX inhibitors |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10849881B2 (en) | Octahydro-cyclobuta[1,2-c;3,4-c′]dipyrrol-2-yl | |
US11098048B2 (en) | Bicyclic compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors | |
US10913745B2 (en) | Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors | |
US11673888B2 (en) | Bicyclic compounds as ATX inhibitors | |
JP6285444B2 (ja) | 新規な二環式誘導体 | |
US9493486B2 (en) | Diazaspirocycloalkane and azaspirocycloalkane | |
NZ711002B2 (en) | New octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: HOFFMANN-LA ROCHE INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:F. HOFFMANN-LA ROCHE AG;REEL/FRAME:041461/0563 Effective date: 20140213 Owner name: F. HOFFMANN-LA ROCHE AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MATTEI, PATRIZIO;HUNZIKER, DANIEL;DI GIORGIO, PATRICK;AND OTHERS;SIGNING DATES FROM 20131210 TO 20131218;REEL/FRAME:041461/0273 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE |